Stockwinners Market Radar for February 22, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:17 EST Xcel Energy raises quarterly dividend by 6.7% to 52c per share - The dividends are payable April 20, 2023, to shareholders of record on March 15, 2023.

19:13 EST Figs says Strategic Partners' litigation against company is over - FIGS issued the following statement with respect to the conclusion of SPI's litigation against FIGS: "Strategic Partners Inc. and FIGS, Inc., have settled all litigation brought by SPI against FIGS. As part of the settlement, all litigation between the parties will end and neither party will make any payments or have any other obligations to the other. This comes three-and-a-half months after a jury in the United States District Court for the Central District of California found in favor of FIGS and rejected all of the claims made by SPI. Following a three-week trial, the jury unanimously concluded in less than a day that FIGS engaged in no wrongdoing of any kind, and that none of FIGS' advertising was false, misleading or deceptive. Moreover, the jury called out SPI's hypocrisy, finding that SPI engaged in the very misconduct that it falsely complained about in the litigation." "The jury verdict was a powerful win, not only for FIGS, but for fair competition," said Todd Maron, Chief Legal Officer at FIGS. "SPI engaged in a nasty, four-year campaign against FIGS, engineered by its former CEO Mike Singer and based on outright falsehoods. SPI had sued competitors at least twice before in similar situations, and we felt it was important to stand up for the truth when confronted with a baseless lawsuit. We're gratified that our decision was vindicated by the jury's verdict, and that SPI was not allowed to stifle another company's growth."

18:38 EST TrueCar reports Q4 units 77,000 vs. 101,000 a year ago - Reports dealers 12,072 vs. 12,495 a year ago.

18:05 EST Roivant Sciences director sells $31.8M in common stock - In a regulatory filing, Roivant Sciences disclosed that its director Vivek Ramaswamy sold 4M shares of common stock on February 22nd in a total transaction size of $31.8M.

18:03 EST Americas Gold and Silver sees FY23 silver output 5.5M-6.0M oz - The Company states that it "expects to continue to increase metal production in 2023. Consolidated attributable silver equivalent production for 2023 is anticipated to be between 5.5 - 6.0 million ounces which compares favorably with 2022 production of 5.3 million silver equivalent ounces. Silver production is expected to increase in 2023 as a result of: i) a higher portion of production coming from the higher-grade silver Upper Zone of the San Rafael deposit at the Cosala Operations; ii) a full year of production from the 3700 Level at the Galena Complex which contains higher grade ore as well as the completion of the Galena Hoist project before H2-2023."

17:57 EST Aravive's batiraxcept granted orphan designation in pancreatic cancer treatment - Aravive's batiraxcept was granted orphan designation by the FDA in the treatment of pancreatic cancer, according to a post to the agency's website.Reference Link

17:28 EST Nvidia sees FY23 capital expenditures $1.1B-$1.3B - Says partnering with cloud service providers to provide Nvidia AI cloud services. Says gamers are responding to latest RTX GPUs. Says agreed to 10-year partnership with Microsoft to include Xbox PC games to the Nvidia GeForce NOW. Says expects sequential growth to be driven by strong data center and gaming performance. Sees Q1 capital expenditures $350M-$400M. Comments and guidance taken from Q4 earnings conference call.

17:17 EST Lucid Group down 8% afterhours at $9.14 after Q4 results and 2023 outlook

17:17 EST Sturm Ruger declares quarterly dividend of 42c per share - For stockholders of record as of March 10, payable on March 24.

17:14 EST TransMedics jumps 14% to $73.72 after Q4 results, above-consensus guidance

17:10 EST Norfolk Southern reaches paid sick leave agreement with engineering railroaders - Norfolk Southern has reached an agreement with one of its largest labor unions that provides their members the ability to take up to seven paid sick days per year. The new sick leave benefit, reached in collaboration with the Brotherhood of Maintenance of Way Employees, is available to approximately 3,000 railroaders who maintain the company's track and infrastructure. The company remains in active discussions with its other union partners to gather input on the issues that are most important to their members.

17:08 EST Callon Petroleum expects 2023 planned capital expenditures of $1B - Highlights: 2023 planned capital expenditures of $1 billion, representing a projected reinvestment rate of ~60%. 2023 production expected to average 104-107 thousand barrels per day of oil equivalent. Adjusted free cash flow from 2023-27 projected to total greater than$2.75B, assuming $80 per barrel NYMEX WTI and current service cost levels, or more than 125% of Callon's current market capitalization. Company expects to continue its rapid pace of debt reduction and reach its key $2B debt milestone in the second half of 2023, based on the current commodity price environment. Five-year outlook characterized by increasing capital efficiency and a projected compounded annual production growth rate of 2%-4%, highlighting the depth of consistent, high-quality inventory and improved cycle times."Our 2023 business plan builds on the strong operational execution and financial outcomes we delivered last year," said Joe Gatto, President and CEO. "We remain committed to consistent capital allocation to our high rate of return projects complemented by debt reduction from our free cash flow. We are confident that our plan will allow us to reduce debt to $2 billion later this year, which is now our financial threshold for implementing plans to return capital to shareholders. Over the next five years, adhering to disciplined reinvestment rates combined with improving capital efficiencies, we project that our investments will generate over $2.75 billion of cumulative adjusted free cash flow."

17:05 EST Cisco COO Martinez sells 20,000 common shares - In a regulatory filing, Cisco Systems COO Maria Martinez disclosed the sale of 20,000 common shares of the company on February 21 at a price of $49.8768 per share.

17:01 EST Amicus reports 'positive' long-term data from Phase 3 study of AT-GAA - Amicus Therapeutics announced "positive" results from the global Phase 3 open-label extension study to investigate the long-term efficacy and safety of AT-GAA in adult patients with late-onset Pompe disease, an inherited lysosomal disorder caused by an enzyme deficiency that leads to the accumulation of glycogen in cells. Study participants treated with AT-GAA for up to 104 weeks showed persistent and durable effects on six-minute walk distance, stability in forced vital capacity, and continued reductions in biomarkers of muscle damage and disease substrate. These clinical results are being featured at the 19th Annual WORLDSymposium 2023 in a poster presentation and an oral platform presentation scheduled for Sunday, February 26, 2023, at 9:00 a.m. ET. The presentation will be given by Benedikt Schoser, MD, Department of Neurology, Ludwig-Maximilians-University of Munich and Principal Investigator in the PROPEL study. Bradley Campbell, President and Chief Executive Officer of Amicus Therapeutics, Inc., stated, "These open label extension data from our Phase 3 PROPEL study of AT-GAA continue to represent meaningful and durable improvements in functional outcomes, as well as persistent reductions in key biomarkers of muscle damage and disease substrate out to two years. These results give great hope that AT-GAA has the potential to become the new global standard of care for people living with Pompe disease."

16:56 EST Nvidia up 7% to $222.35 after Q4 report - Shares of Nvidia are up $14.81, or 7%, to $222.35 in after-hours ahead of the company's earnings call.

16:53 EST Nvidia announces AI cloud service offerings - Nvidia said it is partnering with leading cloud service providers to offer AI-as-a-service that "provides enterprises access to NVIDIA's world-leading AI platform." The company said: "Customers will be able to engage each layer of NVIDIA AI - the AI supercomputer, acceleration libraries software or pretrained generative AI models - as a cloud service. Using their browser, they will be able to engage an NVIDIA DGX(TM) AI supercomputer through the NVIDIA DGX Cloud, which is already offered on Oracle Cloud Infrastructure, with Microsoft Azure, Google Cloud Platform and others expected soon. At the AI platform software layer, they will be able to access NVIDIA AI Enterprise for training and deploying large language models or other AI workloads. And at the AI-model-as-a-service layer, NVIDIA will offer its NeMo and BioNeMo customizable AI models to enterprise customers who want to build proprietary generative AI models and services for their businesses. Further details will be shared at the company's GTC developer conference, taking place virtually March 20-23."

16:51 EST Solaris Oilfield revises 2023 CapEx view to $65M-$75M - Revising previous 2023 capital expenditure guidance to range between $65M-$75M, reflecting an approximately 10%-20% reduction year over year.

16:46 EST Coeur Mining reports 2022 gold reserves 3.4M ounces - Coeur Mining reported year-end 2022 proven and probable reserves of 3.4 million ounces of gold and 245.7 million ounces of silver, reflecting year-over-year increases for both metals with reserve growth at each site, net of depletion. Measured and indicated resources totaled 3.1 million ounces of gold, 181.9 million ounces of silver, 1.4 billion pounds of zinc and 722.2 million pounds of lead. Inferred resources were 1.7 million ounces of gold, 70.0 million ounces of silver, 378.1 million pounds of zinc and 166.0 million pounds of lead. "Solid growth in 2022 gold and silver reserves reflects Coeur's ongoing commitment to investing in higher-return near-mine exploration," said Mitchell J. Krebs, President and Chief Executive Officer. "The Company's large, prospective land positions surrounding its existing assets in stable jurisdictions-including nearly three-quarters of its proven and probable reserves located in the United States-is a key differentiator among precious metals miners as is our five-year track record of material reserve and resource growth. Our exploration investments remain focused on generating attractive returns from near-term priorities, including mine life extensions at Kensington, which we achieved in 2022, medium opportunities for the Company including further resource growth at the high-grade Silvertip project in British Columbia and additional enhancements to Rochester's reserve and resource pipeline."

16:44 EST Chord Energy sees 2023 adjusted EBITDA $1.75B - 2023 E&P and other CapEx is expected to total approximately $825M-$865M, including approximately $20M of CapEx which carried over from 4Q22.

16:41 EST Mosaic provides 2023 capital allocation strategy - "Mosaic remains committed to a disciplined capital allocation strategy. Mosaic anticipates returning virtually all of 2023 generated free cash flow to shareholders through a combination of regular common dividends, special dividends, and share repurchases. Mosaic expects to initiate an accelerated share repurchase of $300 million in first quarter of 2023. Following execution of the ASR, Mosaic will have repurchased shares worth more than $2.5 billion since the third quarter of 2021. As of February 17, shares outstanding totaled 336.5 million shares. Mosaic has a regular common dividend target of $0.80 per share. In an effort to further reward long-term shareholders, Mosaic's Board of Directors has approved a special dividend of $0.25 per share to be distributed on March 30, 2023, to shareholders of record on March 15, 2023. Consistent with the maintenance of a balance sheet reflective of investment grade metrics, Mosaic retired $550 million of long-term debt in November 2022 and met its previously established goal of reducing long-term debt by $1 billion. Management of assets remains a key focus. Mosaic divested Streamsong Resort in January of 2023 for gross proceeds of $160 million. Mosaic will continue to evaluate its capital expenditure budget in 2023. Capex is expected to total $1.3-1.4 billion, with a portion of the spend being directed to projects that we expect will improve operational performance in the phosphates segment. Mosaic is also pursuing high-returning projects. Examples include an expansion of MicroEssentials capacity at our Riverview facility, construction of the new Palmeirante blending and distribution facility in Brazil, construction of a purified phosphoric acid test plant in North America, and extending production from the Taquari potash mine in Brazil. On average, these projects are expected to generate an after tax, internal rate of return of approximately 50%."

16:40 EST LINKBANCORP Inc trading resumes

16:39 EST Bowman Consulting discloses $3M in energy services awards - Bowman Consulting "reported booking $3 million of new renewable energy, solar, electric vehicle, and energy storage assignments during the first 90 days post-closing on SEI Professional Services in November 2022. These assignments vary in size and duration covering multiple customers and geographies. The SEI acquisition added a variety of technical services and experiences to Bowman's portfolio which benefit developers and owners of solar energy facilities along with photovoltaic and battery energy storage operators within the utility and commercial markets."

16:37 EST Cazoo sells Cazana data platform, terms not disclosed - Cazoo Group has sold its third party data platform, Cazana, for an undisclosed sum. The disposal aligns with Cazoo's strategy to focus on its core business as the leading online car buying and selling platform in the UK as opposed to providing data services to third parties, the company said. The agreement includes the sale of the Cazana brand, platform and commercial contracts and Cazoo will continue to benefit from the expertise gained from acquiring Cazana in 2021. The sale is not expected to have any material impact on anticipated revenues for Cazoo in 2023.

16:37 EST Ritchie Bros. issues presentation highlighting benefits of proposed IAA deal - Ritchie Bros. Auctioneers Incorporated (RBA) released a presentation regarding its acquisition of IAA, Inc (IAA) and the reasons Ritchie Bros. shareholders should vote to approve the transaction at the March 14, 2023 Special Meeting of Shareholders. The presentation has been filed with the U.S. Securities and Exchange Commission and is available at www.RBASpecialMeeting.com. Ann Fandozzi, CEO of Ritchie Bros., said, "The IAA transaction is expected to unlock substantial value that neither Ritchie Bros. nor IAA could achieve on its own, and we are confident in our ability to realize it. This confidence is grounded in the extensive due diligence we conducted before entering the IAA agreement, the complementary nature of the IAA asset, management's experience in the auto industry and our Board and management team's record of execution - both in M&A integration and driving successful transformation." "We urge our shareholders to put aside Luxor Capital Group LP's ("Luxor") misleading claims and flawed analysis by voting 'FOR' the IAA acquisition on the WHITE proxy card. The compelling strategic and financial benefits we can create with IAA affirm our strong belief that the IAA acquisition is the most value maximizing opportunity for the Company," continued Fandozzi. Reference Link

16:35 EST Permian Resources raises Fy23 production target by 3% - The company states: "Based on recent operational results, Permian Resources increased its 2023 oil production target by 4% to approximately 85 MBbls/d and raised its total production target by 3% to approximately 162 MBoe/d, based on the mid-point of guidance. Permian Resources also lowered its full year 2023 guidance range for controllable cash costs on a per unit basis by approximately 5%, compared to its preliminary full year outlook. The estimated fiscal year 2023 total capital budget is approximately $1.25 billion to $1.45 billion. Permian Resources expects to turn-in-line approximately 150 gross wells, with an average working interest of approximately 85% and 8/8ths net revenue interest of approximately 78%. This represents an increase from its previously expected full year working interest of 80%. The Company also expects its average completed lateral length during 2023 to increase to approximately 9,300 feet, compared to 9,000 feet previously."

16:34 EST SAP proposes dividend of EUR2.05 per share - The Supervisory Board and Executive Board of SAP have decided to recommend that shareholders approve a dividend of EUR2.05 per share for fiscal year 2022. This is an increase of EUR0.10, or 5% compared to the regular dividend paid for fiscal year 2021. The dividend for 2021 consisted of a regular dividend of EUR1.95 and a special dividend of EUR0.50 in celebration of SAP SE's 50th anniversary for a total dividend of EUR2.45. If approved by shareholders and assuming the same level of treasury shares, the total amount distributed in dividends would be approximately EUR2.4B, representing a pay-out ratio of 140%.

16:34 EST LinkBancorp and Partners Bancorp to combine in merger of equals - LinkBancorp (LNKB) and Partners Bancorp (PTRS) have entered into a definitive agreement under which the companies will combine in an all-stock combination, valued at approximately $167.8M. Partners shareholders will receive 1.15 shares of LINK stock for each Partners share they own. Upon completion of the transaction, Partners shareholders will own approximately 56% and LINK shareholders, inclusive of shares issued in a concurrent private placement of common stock, will own approximately 44% of the combined company. In connection with the transaction LINK has completed a private placement common stock offering resulting in $10M in gross proceeds. Once the merger transaction is completed, the combined organization will be a Mid-Atlantic community banking franchise with nearly $3B in assets and an expected $300+M market capitalization. The combined bank holding company will operate under the LinkBancorp name, and the combined bank subsidiary will operate as Linkbank. Each of Partners' subsidiary banks will merge with and into LinkBank. Partners executives will lead the Delmarva/Maryland, Northern Virginia and Fredericksburg regions for the combined entity. The corporate headquarters of the combined bank holding company and combined bank entity will be located in Camp Hill, Pennsylvania, and will retain a major operating presence in both Salisbury, Maryland and Fredericksburg, Virginia. The combined company will trade under the LinkBancorp ticker symbol "LNKB" on Nasdaq. The combined company's board of directors will have twenty-two directors, consisting of twelve directors from Link and ten directors from Partners. Joseph Michetti, Jr., Link's current Chairman, will continue to serve as Chairman of the combined company board of directors. Jeffery Turner, Partner's current Chairman, will serve as Vice Chairman of the combined company board of directors until September 2024, when Turner will be appointed Chairman of Link, and will be under the leadership of Andrew Samuel, Link's CEO. The transaction is expected to provide 23%+ GAAP EPS accretion in 2024 to Link, 50%+ GAAP EPS accretion in 2024 to Partners, 2.7 years earnback time period of GAAP TBV dilution to Link, 0.6 years earnback time period of TBV dilution excluding AOCI/interest rate marks to Link, and to be 115% accretive to Partner's current cash dividends per share. The merger is expected to close in Q3.

16:33 EST Thermo Fisher raises quarterly dividend 17% to 35c per share - Thermo Fisher Scientific announced that its Board of Directors has authorized a quarterly cash dividend of $0.35 per common share payable on April 14, 2023, to stockholders of record as of March 15, 2023. This reflects a 17% increase over the previous dividend payment of $0.30.

16:32 EST Mr. Cooper names Pelayo chief legal officer - Mr. Cooper Group announced the appointment of Carlos M. Pelayo as Executive Vice President and Chief Legal Officer. Pelayo will lead the company's legal department and corporate governance functions and will serve on the executive leadership team. "We are pleased to welcome Carlos to the Mr. Cooper Group executive leadership team," said Jay Bray, Chairman and CEO of Mr. Cooper Group. "Carlos' experience as a legal executive and leader within several large and complex financial services organizations will be a great fit for our team as we continue our journey of being a great place to work for our team members, strive to achieve our goal of becoming a $1 trillion+ servicer and deliver superior shareholder returns."

16:31 EST Altice USA reports Q4 broadband organic net additions down 7.7K - Q4 Residential ending customer relationships were 4.50M vs. 4.63M y/y.

16:26 EST SM Energy sees Q1 production 12.9-13.1 MMBoe - Sees Q1 average production 143-146 MBoe/d, at 42-43% oil. Sees Q1 CapEx $320M-$330M.

16:23 EST M&T Bank raises quarterly dividend to $1.30 from $1.20 per share - The dividend will be payable March 31 to shareholders of record at the close of business on March 6.

16:20 EST Pioneer Natural sees FY23 Capital Budget $4.45B-$4.75B - The Company expects its 2023 drilling, completions, facilities and water infrastructure capital budget to range between $4.45 billion to $4.75 billion. Additionally, the Company expects its capital budget for exploration, environmental and other capital to range between $150 million to $200 million, principally related to drilling four Barnett/Woodford formation wells in the Midland Basin, additional testing of the Company's enhanced oil recovery (EOR) project and adding electric power infrastructure for future drilling, completions and production operations. Pioneer expects its capital program to be funded from 2023 cash flow, which is projected to be approximately $9 billion. During 2023, the Company plans to operate an average of 24 to 26 horizontal drilling rigs in the Midland Basin, including a three-rig average program in the southern Midland Basin joint venture area. The 2023 capital program is expected to place 500 to 530 wells on production. Pioneer expects 2023 oil production of 357 to 372 thousand barrels of oil per day (MBOPD) and total production of 670 to 700 thousand barrels of oil equivalent per day (MBOEPD).

16:20 EST Pioneer Natural sees Q1 oil production 349-364 MBOPD - First quarter 2023 oil production is forecasted to average between 349 to 364 MBOPD and total production is expected to average between 659 to 687 MBOEPD. Production costs are expected to average $11.75 per BOE to $13.25 per BOE. DD&A expense is expected to average $10.50 per BOE to $12.00 per BOE. Total exploration and abandonments expense is forecasted to be $10 million to $20 million. G&A expense is expected to be $78 million to $88 million. Interest expense is expected to be $27 million to $32 million. Other expense is forecasted to be $20 million to $40 million. The cash flow impact related to purchases and sales of oil and gas, including firm transportation, is expected to be a loss of $50 million to a loss of $90 million, based on forward oil price estimates for the quarter. The Company's effective income tax rate is expected to be 22% to 27%, with cash taxes expected to be $70 million to $100 million, representing estimated federal and state tax payments that will be paid based on forecasted 2023 taxable income.

16:18 EST Consensus Cloud identified 'unintentional errors' in financial statements - onsensus Cloud Solutions said, "During the preparation of its annual report on Form 10-K for the fiscal year ended December 31, 2022, the Company identified unintentional errors primarily relating to (i) to a legacy accounting practice, inherited from the spin transaction in its SoHo business that grossed up revenue by $1.9 million and $5.3 million for the three and nine month periods ended September 30, 2022, respectively, with a corresponding offset to bad debt expense ("SoHo Error") and (ii) the timing of revenue recognition of $2.2 million and $2.5 million for the three and nine month periods ended September 30, 2022, respectively, which after review, the Company has concluded should be reclassified as deferred revenue ("Deferred Revenue Error"). The correction of the SoHo Error has no impact on the Company's operating income, net income, EBITDA or cash flows for the relevant periods. The correction of the Deferred Revenue Error affects the timing of revenue recognition for the applicable arrangement, but not the amount of revenue that will be recognized over time for the applicable arrangement. Neither error has any impact on the Company's cash or cash equivalents. On February 21, 2023, as a result of the unintentional errors noted above, the audit committee of the board of directors of the Company reached a determination to restate its unaudited financial statements for the three and nine month periods ended September 30, 2022. "

16:17 EST Strategic Education says Q4 USHE student enrollment was down 0.8% y/y - The company states: "The U.S. Higher Education segment (USHE) is comprised of Strayer University and Capella University. For the fourth quarter, student enrollment within USHE decreased 0.8% to 78,062 compared to 78,721 for the same period in 2021. Full-year 2022 student enrollment within USHE decreased 6.5% compared to 2021. For the fourth quarter, FlexPath enrollment was 19% of USHE enrollment compared to 18% for the same period in 2021."

16:11 EST Coterra Energy sees FY23 capital investment $2B-$2.2B - Sees FY23 average production 610-650 MBoe/d. "Guided by principles focused on full-cycle value creation and disciplined capital allocation, Coterra expects to invest approximately 50 percent of its cash flow, at recent strip prices", commented Jorden. "This is expected to result in a 2023 production profile that will be relatively flat year-over-year before returning to modest growth in 2024 and 2025. Coterra's dynamic organization, top-tier assets and industry-leading balance sheet are poised to generate long-term consistent profitable growth."

16:09 EST Lucid Group: 2023 production guidance of 10,000 -14,000 vehicles

16:07 EST Comfort Systems USA raises quarterly dividend to 17.5c per share from 15c - Comfort Systems USA announced that its board of directors declared a quarterly dividend of $0.175 per share, which is a $0.025 increase from the Company's most recent dividend, on Comfort Systems USA, Inc. common stock. The dividend is payable on March 21, 2023 to stockholders of record at the close of business on March 10, 2023.

16:05 EST Sangamo sees FY23 operating expenses of $275M-$295M - The company states: "We expect non-GAAP total operating expenses, excluding estimated non-cash stock-based compensation expense of approximately $35 million, in the range of approximately $275 million to $295 million in 2023."

16:00 EST Partners Bancorp trading halted, news pending

16:00 EST LINKBANCORP Inc trading halted, news pending

15:29 EST Chanos says still short Sunrun - Jim Chanos is discussing his Sunrun short position while being interviewed on CNBC.

15:25 EST GE earnings estimates 'just continue to get cut' since spinoff plan, Chanos says - Jim Chanos is discussing his short position on GE during an interview on CNBC.

15:20 EST Chanos says 'we are still short' Coinbase - Jim Chanos, president and founder of Kynikos Associates, said while being interviewed on CNBC that he is "still short" Coinbase.

15:08 EST Netflix announces first partnership with NFL for 'Quarterback' docu-series - Netflix announced what it called "its first partnership with the NFL" for "Quarterback," a new docu-series "that will take a unique look at each season, told through the lens of NFL quarterbacks." Netflix said: "This year, the series features exclusive, unprecedented access to Patrick Mahomes, Kirk Cousins and Marcus Mariota from the beginning of the 2022 season to its conclusion, following them on and off the field, from inside the huddle with teammates to inside their homes with their families. It will premiere in summer 2023." Reference Link

15:04 EST Old Point Financial increases quarterly cash dividend 7.7% to 14c per share - Old Point Financial declared a quarterly cash dividend of 14c per share on its common stock to be paid on March 31 to shareholders of record as of March 8. This dividend represents a 1c per share increase, or 7.7%, from the prior quarter's dividend and is also a 1c increase from the prior year's quarterly dividend level. Based on the stock's closing price of $25.95 on February 21, the dividend yield is approximately 2.2%.

15:04 EST Regenxbio announces additional 'positive' interim data from CAMPSIITE trial - Regenxbio announced additional "positive" interim data from the Phase I/II/III CAMPSIITE trial of RGX-121 for the treatment of patients up to 5 years old diagnosed with Mucopolysaccharidosis Type II, or MPS II, also known as Hunter Syndrome. The results were presented at the 19th Annual WORLDSymposium. "These new results demonstrate sustained reductions in CSF GAGs and an encouraging, long-term clinical profile of RGX-121 up to three years," said Steve Pakola, M.D., Chief Medical Officer of Regenxbio. "GAGs measured in CSF, specifically heparan sulfate, reflect disease manifestations in the CNS and are a direct cause of disease pathophysiology. Our data provide additional evidence to support the finding that meaningful changes in CSF heparan sulfate is an appropriate and reliable surrogate endpoint reasonably likely to predict the clinical benefit of CNS-targeted therapies for MPS II. We are excited to have taken RGX-121 into a pivotal program and plan to file a Biologics License Application in 2024 using the accelerated approval pathway."

14:30 EST Tiffany says Nike/Tiffany Air Force 1 1837 list opening March 3 - In a post to its website, Tiffany (TIF) stated: "The collaboration is focused on a limited-edition black Nike/Tiffany Air Force 1 1837 shoe. A series of sterling silver accessories has also been designed exclusively for the collaboration, including a whistle pendant, shoe horn, shoe brush and ornamental shoelace dubrae for the Nike/Tiffany Air Force 1 1837... Due to the very exclusive nature of the Nike/Tiffany collaboration and the expected high demand, purchases will follow the timeline below. - On March 3 for a limited time, clients may enroll online for an opportunity to purchase; Starting March 6, clients will be notified regarding their enrollment outcome and if their order is confirmed or not; On March 7, confirmed delivery orders will start to process, and confirmed pickup orders will be available at two Tiffany & Co. locations in New York city (Soho or Flagship Next Door)."

13:46 EST Bandai Namco says 'Elden Ring' has shipped over 20M units worldwide - Bandai Namco (NCBDY) and FromSoftwarae announced that action-RPG "Elden Ring" has shipped more than 20M units worldwide since its February 25, 2022 release. The game is available on PlayStation 4 (SONY), PS5, Xbox One (MSFT), Xbox Series X/S, and PC via Steam. Reference Link

13:34 EST Google, Mercedes-Benz announce long-term strategic partnership for navigation - Mercedes-Benz (MBGYY) and Google (GOOGL) announced a long-term strategic partnership to "further accelerate auto innovation and create the industry's next-generation digital luxury car experience." The companies stated: "With this partnership, Mercedes-Benz will be the first automaker to build its own branded navigation experience based on new in-car data and navigation capabilities from Google Maps Platform. This will give the luxury automaker access to Google's leading geospatial offering, including detailed information about places, real-time and predictive traffic information, automatic rerouting, and more. By embedding these features into the upcoming Mercedes-Benz Operating System, customers will be able to enjoy a superior navigation experience, thanks to easy usability and outstanding graphics on the car's high-resolution screen. To help enrich the user experience, the companies will bring the YouTube app into the Mercedes-Benz infotainment system. In addition, Mercedes-Benz will use Google Maps data to enable assisted driving features such as automatic speed adjustments before intersections, roundabouts or curves."

13:26 EST North American rail traffic down 4% for the week ending February 18 - The Association of American Railroads, AAR reported U.S. rail traffic for the week ending February 18. For this week, total U.S. weekly rail traffic was 466,932 carloads and intermodal units, down 6.5% compared with the same week last year. Total carloads for the week ending February 18 were 229,227 carloads, down 3.9% compared with the same week in 2022, while U.S. weekly intermodal volume was 237,705 containers and trailers, down 8.8% compared to 2022.Four of the 10 carload commodity groups posted an increase compared with the same week in 2022. They included motor vehicles and parts, up 1,396 carloads, to 13,664; petroleum and petroleum products, up 1,378 carloads, to 10,630; and farm products excl. grain, and food, up 940 carloads, to 17,132. Commodity groups that posted decreases compared with the same week in 2022 included coal, down 6,178 carloads, to 66,566; grain, down 3,118 carloads, to 21,864; and miscellaneous carloads, down 1,419 carloads, to 7,843. North American rail volume for the week ending February 18, on 12 reporting U.S., Canadian and Mexican railroads totaled 335,772 carloads, up 0.3% compared with the same week last year, and 313,084 intermodal units, down 8.3% compared with last year. Total combined weekly rail traffic in North America was 648,856 carloads and intermodal units, down 4%. North American rail volume for the first seven weeks of 2023 was 4,461,274 carloads and intermodal units, down 2.2% compared with 2022.Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific (CP), Kansas City Southern (KSU), Norfolk Southern (NSC) , Union Pacific (UNP), Greenbrier (GBX), Trinity Industries (TRN), FreightCar America (RAIL) and Wabtec (WAB). Reference Link

13:02 EST BTU Metals announces agreements with Kinross Gold - BTU Metals (BTUMF) announced that it has entered into a series of transactions with Kinross Gold (KGC) that "will strengthen the exploration effort on the significant properties of BTU in the Great Bear gold area southeast of the main Red Lake Gold camp area of northwestern Ontario. The Dixie Halo Project is located adjacent to Kinross's Great Bear project, BTU noted. The transactions include: a purchase agreement pursuant to which Great Bear Resources Ltd., a wholly-owned subsidiary of Kinross, acquired from BTU certain unpatented mining claims located in the Kenora District of Ontario, with BTU continuing to participate in those lands through a newly created royalty payable to BTU; an option agreement, which provides GBR with an option to earn a 70% interest in certain unpatented mining claims held by BTU located in the Kenora District of Ontario; and a subscription agreement pursuant to which Kinross purchased 25M common shares of BTU at a purchase price of CAD$0.05 per common share. BTU CEO Paul Wood commented; "We are very pleased to enter into this series of transactions with Kinross, which will: provide CAD$2.8M in cash to the company by way of a private placement and property sale, accelerate the exploration of BTU's properties through an earn-in agreement of up to CAD$4.7M, and, in all cases, leave substantial upside for BTU shareholders through a royalty package and its at least 30% interests in the Optioned Properties of the Dixie Halo Project. BTU will fully support Kinross as they commence their exploration work on the Optioned Properties and we are very pleased to have Kinross as a partner. The company is also in the process of sourcing, accepting and assessing new and complementary minerals exploration projects to add to and diversify our property portfolio."

12:44 EST Southland Holdings Inc trading halted, volatility trading pause

12:37 EST Nucor to build new transmission tower production plant in Alabama - Nucor announced today that the company's Towers & Structures business unit will build a new transmission tower production plant in Decatur, Alabama. The new plant will be located adjacent to the Nucor Steel Decatur sheet steel mill and will be the first of two new tower production plants the company plans to build. "The plant in Alabama will be highly automated, utilizing efficient straight-line production, and will also include advanced hot-dip galvanizing operations. These state-of-the-art features will increase Nucor Towers & Structures' capabilities to provide engineered solutions for utility infrastructure and construction projects. The company continues to evaluate potential sites in the U.S. Midwest to build a second tower production plant... Last year, Nucor formed its Nucor Towers & Structures business unit when it acquired Summit Utility Structures LLC, a producer of metal poles and other steel structures for utility infrastructure. In December, the company announced plans to establish a nationwide footprint by building two new tower production plants for a combined investment of $270 million dollars," the company said.

12:32 EST UnitedHealth, Somatus expand kidney care agreement to five states - Somatus and UnitedHealthcare announced the expansion of their value-based partnership to now include providing high-touch kidney care services to thousands of new members throughout Connecticut, Illinois, Massachusetts, New Jersey, and Rhode Island who have chronic kidney disease or end-stage kidney disease. Somatus' partnership with UnitedHealthcare expands the company's geographic footprint to 36 states, including D.C., and increases the number of program members to more than 160,000 under management in 2023. Somatus' impressive growth across all industry stakeholders reflects its demonstrated ability to improve the quality of care and lower unnecessary medical costs.

12:01 EST Charles River falls -14.5% - Charles River is down -14.5%, or -$35.38 to $208.22.

12:01 EST ZipRecruiter falls -24.4% - ZipRecruiter is down -24.4%, or -$5.67 to $17.59.

12:00 EST Fiverr rises 17.6% - Fiverr is up 17.6%, or $6.65 to $44.42.

11:46 EST Richmond Mutual Bancorp increases quarterly dividend 40% to 14c per share - Richmond Mutual Bancorporation announced that its Board of Directors has declared a cash dividend on Richmond Mutual Bancorporation common stock of 14c per share, which represents a 40% increase over the 10c per share quarterly dividend declared in November 2022. The cash dividend will be payable on March 16, 2023 to stockholders of record as of the close of business on March 2, 2023.

11:29 EST TJX expects to repurchase $2B-$2.5B of TJX stock this FY - The company expects its board will increase the quarterly dividend by 13%.

11:21 EST Dick's Sporting acquires outdoor retailer Moosejaw from Walmart - Dick's Sporting Goods (DKS) announced it has agreed to acquire outdoor retailer Moosejaw from Walmart (WMT). The acquisition will expand Dick's outdoor portfolio and "reaffirm its commitment to the long-term business opportunity in the growing multibillion-dollar outdoor category," the company said in a statement. The deal is expected to close in March 2023. Terms were not disclosed.

11:17 EST Genmab announces 220,000 share buyback program - Genmab announced that it is initiating a share buyback program of up to 220,000 shares. The program will start on February 23 and end on March 31.

10:49 EST Watchdog decides against fine after Tesla makes changes to security cameras - Car manufacturer Tesla has made the settings of its cars' built-in security cameras more privacy-friendly, following an investigation into the cameras by the Dutch Data Protection Authority. The DPA conducted an investigation into the Sentry Mode in Tesla vehicles. Tesla has informed the DPA that, since the launch of the investigation, the company has made various changes to the Sentry Mode feature. For instance, now it responds only if the vehicle is touched, and not as soon as the cameras detect suspicious activity around the vehicle. In addition, the vehicle does not automatically begin filming but the owner receives an alert on their phone. The vehicle can still record camera footage, but only when the user enables this function. If the camera is recording, the vehicle will display a message to this effect on the touchscreen inside the car and the headlights will pulse. The DPA's investigation has not resulted in a fine or other sanction for Tesla. Reference Link

10:19 EST Citizens enters white label distribution agreement with Amerus - Citizens announced that it has expanded its white-label program by entering into a new distribution agreement with Amerus Financial Group. Under this partnership, Amerus will sell Citizens' life and final expense insurance products marketed with the Amerus Silver Shield brand. These products will be sold through CICA Life Insurance Company of America, a Citizens company.

10:02 EST LUNR Stock trading resumes

10:00 EST Charles River falls -10.1% - Charles River is down -10.1%, or -$24.60 to $219.00.

10:00 EST ZipRecruiter falls -18.3% - ZipRecruiter is down -18.3%, or -$4.26 to $18.99.

10:00 EST Brookdale Senior Living rises 16.5% - Brookdale Senior Living is up 16.5%, or 50c to $3.52.

09:52 EST LUNR Stock trading halted, volatility trading pause

09:47 EST Keysight Technologies falls -11.8% - Keysight Technologies is down -11.8%, or -$21.53 to $161.45.

09:47 EST Vertiv Holdings rises 11.6% - Vertiv Holdings is up 11.6%, or $1.77 to $17.03.

09:47 EST Fiverr rises 19.9% - Fiverr is up 19.9%, or $7.53 to $45.30.

09:41 EST IMARA trading resumes

09:34 EST Co-Diagnostics commences clinical evaluations for Co-Dx PCR Home platform - Co-Diagnostics has commenced clinical evaluations for its at-home and point-of-care Co-Dx PCR Home platform and initial COVID-19 test, consisting of the clinical trials and analytical studies that are expected to support submissions to the United States FDA and other regulatory bodies. The Company's real-time PCR platform has been developed for detection of infectious diseases in at-home and point-of-care settings, with anticipated multiplex panels to follow after receipt of the platform's initial regulatory authorization. Because the evaluations are dependent on identifying and enrolling a particular number of both symptomatic and asymptomatic COVID-19-positive and -negative patients at testing sites, the Company will not be providing projected timelines for completion at this time.

09:31 EST Adamas One announces $7.5M share repurchase program - Adamas One announces that its Board of Directors has authorized a share repurchase program to repurchase up to $7.5M of Adamas One's outstanding common stock. This share repurchase authorization is effective immediately.

09:31 EST IMARA trading halted, volatility trading pause

09:21 EST Synchronoss to showcase AI-powered Personal Cloud platform - Synchronoss announced it will showcase the latest version of Synchronoss Personal Cloud at Mobile World Congress in Barcelona, Spain. The new Synchronoss Personal Cloud platform enables telecom operators to offer premium and value-added services to backup and manage files, photos, videos, and digital content stored on mobile phones and other devices.

09:19 EST Nuvei completes $1.3B acquisition of Paya Holdings - Nuvei Corporation completed its acquisition of Paya Holdings. Paya amplifies Nuvei's existing growth strategy and expands its reach into new underpenetrated and non-cyclical verticals where Nuvei's proprietary technology is well positioned to accelerate customer growth. Nuvei Chair and CEO Philip Fayer commented, "This is an important milestone for Nuvei as we continue to build a preeminent payment technology provider with strong positions in global eCommerce, Integrated Payments and B2B. I'm thrilled to officially welcome our new colleagues from Paya to the Nuvei family. We have been working diligently on our integration planning, and we are ready to begin the next step on this exciting journey as a single, unified team."

09:13 EST Sage Group announces series of updates for Sage Intacct - Sage announces a series of updates to Sage Intacct. From simplifying and automating bill processing to increasing visibility, businesses globally will benefit from smoother processes and increased productivity as part of Sage Intacct 2023 Release 1. Key product enhancement in Sage Intacct 2023 Release 1 include: Accounts Payable Bill Automation - Today, a third of typical AP process time for medium-sized businesses is spent on invoice entry1. With Sage's AI-powered bill entry, customers can save up to half of that time on AP processing. Coupled with other Sage Intacct AP capabilities, including paperless approval routing, automated payment processing, automated reconciliation, and reporting, customers can manage their entire AP process within Sage Intacct. The solution has no monthly subscription or implementation fee. Customers pay based on what they use, making it more affordable for smaller midsize organizations. Availability: This solution is now generally available in the US through direct and reseller channels. In Canada, the United Kingdom, South Africa, and Australia, the solution is currently available to select customers via an early adopter program. Mateo Savings and Loan - Since its acquisition of Mateo less than a year ago, Sage has already invested significantly to enhance functionality for the leading cloud-based Roman Catholic diocesan savings and loans solution on the market. The latest updates include improved flexibility for financial statement generation, streamlined workflows, and expanded import capabilities. Availability: The latest enhancements to Mateo are now generally available in the US. Automating usage billing for subscriptions - Sage continues to simplify billing by making Sage Intacct the first midmarket accounting and ERP solution to automate usage billing for evergreen subscriptions. As a result, users can automate their financial processes without the need to bolt-on third party billing applications, delivering simpler and real-time visibility and minimizing complexities like contract amendments, usage, one-time, and subscription billing to grow their businesses. Availability: These enhancements are now available in the US, Canada, UK, South Africa, and Australia.

09:12 EST Flywire partners with FranConnect to provide B2B payments solution - Flywire Corporation is announcing a partnership with FranConnect, the market leader in franchise management technology, to streamline the payment experience for franchisors looking to grow their businesses both domestically and internationally. The partnership between Flywire and FranConnect is designed to provide franchisors more efficiency and access to analytics that enable them to accelerate the payment collection process. Flywire integrates directly into the FranConnect software, helping franchisors to automatically power every transaction, ranging from the initial payments required to sign a franchise agreement, all the way through to managing the ongoing royalty and fee payments from franchisees. Because franchisors can leverage Flywire all from within the familiar FranConnect platform, they can benefit from the ability to easily track and access payments, and to quickly and efficiently settle and reconcile payments. "We're thrilled to partner with Flywire and integrate their B2B payments platform into our marketplace," said Gabby Wong, CEO, FranConnect. The integration between Flywire and FranConnect enables franchisors to overcome these common hurdles by providing a streamlined payment experience that can be tailored to their franchisees around the world.

09:10 EST Amazon completes acquisition of One Medical - Amazon (AMZN) and 1Life Healthcare (ONEM) announced that Amazon completed its acquisition of One Medical. Together, Amazon and One Medical look to deliver exceptional health care to more people to achieve better health outcomes, better care experiences, and more value, within a better care team environment. For a limited time, One Medical is offering annual memberships at the discounted price of $144 for the first year, the equivalent of $12 per month, to new customers. Redeem the One Medical membership promotion and learn more about what's included.

09:10 EST Planet and ASU team to build global scale solutions for sustainability - Planet Labs announced that they have solidified a Strategic Partnership with Arizona State University to facilitate climate action through education and research, workforce development, and a science-first approach toward innovation. Since 2016, Planet and ASU have collaborated on significant programs including the Planet Incubator Program within ASU's Center for Global Discovery and Conservation Science, the development of the Allen Coral Atlas, as well as two of the founding partners in the creation of the Carbon Mapper mission. In early 2019, ASU became Planet's first campus-wide university partner, and since then, over 30 peer reviewed journal articles have been published by ASU using Planet products. Planet and ASU continue to be leaders in creating an ecosystem for 21st century learning and innovation focused on accelerating scalable climate-action and mission-oriented business. This partnership will align their shared strategic focus to train and hire world class talent and be a catalyst to innovations in science, technology, and the use of space for increased sustainability of life on Earth.

09:08 EST Vicor announces global distribution agreement with Avnet - Vicor Corporation (VICR) announced its distribution agreement with Avnet (AVT), a global distributor of electronic components and services. The agreement expands access to Vicor's power modules through Avnet's world-class design and supply chain, enabling global customers to achieve world-changing innovation with higher system performance and greater scalability. "This is a great opportunity for Vicor to partner with a global leader aligned with Vicor's target markets," said David Krakauer, VP Industrial Business Unit and Corporate Marketing. "Working with Avnet will better position Vicor to bring our highly differentiated modular power solutions to customers who wish to unleash the power of their own innovations."

09:07 EST AMD expands support of 5G partner ecosystem - AMD will be expanding support of its growing 5G partner ecosystem spanning from core to radio access networks applications, delivering additional new test capabilities and unveiling new 5G products. The AMD wireless telecom partner ecosystem has more than doubled in the past year, bolstered by the integration of the AMD and Xilinx product lines as well as the creation of its new Telco Solutions testing lab in collaboration with VIAVI. The formation of the Telco Solutions testing lab is vital for operators and telco solution providers to test, validate and scale computing resources to deliver on the ever-increasing demands from RAN and edge-to-core. The testing lab supports validation of end-to-end solutions, including both hardware to software to leverage the performance and power efficiencies of the latest AMD processors, Adaptive SoCs, SmartNICs, FPGAs and DPUs. As part of the growing AMD telco ecosystem, AMD and Nokia are jointly announcing an expanded collaboration using 4th Gen AMD EPYC processor-based servers to deliver Nokia Cloud RAN solutions to help communications service providers achieve their most stringent energy efficiency goals. AMD and Nokia recognize the challenges faced by operators dealing with spiraling energy costs and the growing importance of meeting carbon reduction targets at the core as well as the network edge.

09:04 EST 22nd Century accelerates major seed cultivation project - 22nd Century Group accelerated a major seed cultivation project for its proprietary reduced nicotine content tobaccos to support local authorities as they work to implement New Zealand's new reduced nicotine content law starting from this year. The seed will be used to rapidly scale the availability of 22nd Century's reduced nicotine content tobacco leaf to manufacture cigarettes compliant with New Zealand's new reduced nicotine content law. 22nd Century's proprietary reduced nicotine content tobacco varieties grow with 95% less nicotine than the commercial tobaccos used in making cigarettes for the New Zealand market. Significantly, 22nd Century's non-GMO tobacco varieties are already compliant with the New Zealand law, which requires all combustible cigarettes to contain less than 0.8 mg of nicotine per gram of tobacco, inclusive of testing variance. 22nd Century's expanded growing program, centered in the heart of the US tobacco belt, will produce additional seed sufficient for approximately 2 billion sticks, the entire annual New Zealand cigarette market volume.

09:03 EST Heron Therapeutics announces cooperation agreement with Rubric and Velan - Heron Therapeutics announced that it has entered into a cooperation agreement with two of its shareholders, Rubric Capital Management and Velan Capital Investment Management. As part of the agreement, Heron has agreed to appoint Craig Collard, former President & CEO at Veloxis Pharmaceuticals, and Adam Morgan, Chief Investment Officer at Velan, to the Company's Board of Directors. Additionally, as a result of Heron's ongoing refreshment process, the Company will appoint Kevin Kotler, Founder and Portfolio Manager of Broadfin Capital, to the Board. Current directors Stephen Davis and Kimberly Manhard will be leaving the Board. With these changes, the Heron Board will expand to eight directors, seven of whom are independent, and all of whom will stand for election to the Board at the upcoming 2023 Annual Meeting. Heron also announced it will separate the roles of Chairman and CEO after the conclusion of its 2023 Annual Meeting. Under the terms of the cooperation agreement, Rubric and Velan have agreed to customary standstill, voting commitments and other provisions. A copy of the cooperation agreement will be included in a Form 8-K filed with the U.S. Securities and Exchange Commission.

09:02 EST Marvell, AWS collaborate on electronic design automation - Marvell Technology (MRVL) announced that it has selected Amazon Web Services (AMZN) as its cloud provider for electronic design automation. A cloud-first approach helps Marvell to rapidly and securely scale its service on the world's leading cloud, rise to the challenges brought by increasingly complex chip design processes, and deliver continuous innovation for the expanding needs across the automotive, carrier, data center, and enterprise infrastructure markets it serves. The work extends the longstanding relationship between the two companies-Marvell is also a key semiconductor supplier for AWS, helping the company support the design and rapid delivery of cloud services that best meet customers' demanding requirements.

08:54 EST Diana Shipping board to increase size from nine to eleven members - The Company's board of directors has determined to increase the size of the board from nine to eleven members, effective February 22, 2023. Mr. Eleftherios Papatrifon will be transitioning from the role of Chief Operating Officer to a member of the board of directors and an executive committee member, and Ms. Jane Chao will fill the second vacancy resulting from the increase in the size of the board of directors. Chao is a businessperson with many years of diverse experiences and successes in real estate, hotel and food and beverage industries, she is also a Director of Wah Kwong

08:46 EST Arteris IP launches Arteris FlexNoC 5 physically aware network-on-chip IP - Arteris announced the launch of Arteris FlexNoC 5 physically aware network-on-chip interconnect IP. FlexNoC 5 enables SoC architecture teams, logic designers and integrators to incorporate physical constraint management across power, performance and area to deliver a physically aware IP connecting the SoC. This technology enables 5X faster physical convergence over manual refinements with fewer iterations from the layout team for automotive, communications, consumer electronics, enterprise computing, and industrial applications. Manual workflows typically include numerous iterations of pipeline insertions, effort-intensive creation of constraints for physical placement of units, and lengthy NoC placement plus route iterations to converge on the SoC PPA targets. By contrast, FlexNoC 5 physical awareness eliminates these iterations and shortens the duration of various manual steps, facilitating up to 5X faster physical convergence of the back-end physical design time and effort. The resulting physically optimized NoC IP instance is then ready for output to physical synthesis and place and route for implementation.

08:42 EST Amdocs, Drei Austria collaborate to launch digital eSIM experience - Amdocs has enabled Drei Austria to launch an eSIM solution allowing the Austrian operator's customers to enjoy the benefits of digital eSIM technology in a purely app-based experience. An eSIM is an embedded, digital SIM that lets users activate a cellular plan from a mobile network operator without the need for a physical SIM card. While many operators require customers to use QR codes to activate an eSIM, the Drei Austria solution - powered by Amdocs' eSIM platform - allows for app-based activation and full lifecycle management through Drei Austria's new app and 100% digital 5G unlimited mobile subscription plan, up. Drei Austria customers who use the up app can now manage their eSIM on devices produced by Apple, Google, Samsung and more.

08:41 EST Nano Dimension holder Murchinson says board 'sabotages' shareholder rights - Murchinson the largest shareholder with approximately 5.2% of the outstanding shares of Nano Dimension, issued a statement regarding the importance of shareholders voting at the upcoming Special General Meeting of Shareholders, in spite of the myriad efforts by Nano Dimension's current Board of Directors to undermine the meeting: "Since the moment we exercised our legal right as shareholders to call the upcoming Special Meeting, the Yoav Stern-led Board of Nano Dimension has consistently sought to sabotage it and prevent shareholders' voices from being heard - including by disseminating false and highly misleading statements while seeking to deflect the discussion and maintain the status quo. The Board's framing of the Special Meeting as another step in a hostile takeover attempt that will allow Murchinson to somehow secure a windfall at shareholders' expense is demonstrably untrue. Instead, it is apparent that the Board's adamant refusal to acknowledge the validity of the Special Meeting - which was lawfully called - proves why enhanced corporate governance and proper oversight are required at Nano Dimension. In our view, the brazen attempt to subvert the legal process by calling the Special Meeting illegal is only the latest piece of evidence demonstrating the need for urgent change at the board level of the Company.

08:40 EST Atlis Motor successfully demonstrates over 1 megawatt charging capability - Atlis Motor Vehicles announced successful demonstration of their ability to charge over 1 Megawatt. This is a significant milestone and marks a critical step towards realizing the Company's vision of establishing a 1.5MW charging network. Improving charging customer experience and increasing access to adequate infrastructure is fundamental to accelerating the adoption of electrified vehicles across sectors, especially Atlis' target market segment. "Simply put, the state of charging capability and infrastructure in America is impeding progress. Whether your concern is commercial charging capability or access to consumer charging, one thing we know for certain is that the system is broken," said Mark Hanchett, Founder and CEO of Atlis Motor Vehicles. "For business owners, uptime is the bottom-line. Widespread commercial infrastructure is the missing piece for many looking to transition their fleets to electric, and Atlis is ready to answer the call."

08:38 EST iCoreConnect announces partnership with Yankee Alliance - iCoreConnect announced its partnership with Yankee Alliance, a nationwide group purchasing organization, GPO, for business in all classes of trade with nearly 20,000 members. The partnership expands iCoreConnect's presence in the medical space. iCoreConnect's partnership with Yankee Alliance is the company's first with a national GPO. The two companies will jointly market to the Yankee Alliance member base, introducing multiple products from the iCoreConnect platform. Robert McDermott, President and CEO of iCoreConnect, commented, "This new partnership springboards us further into the medical field. Yankee Alliance is a tremendous GPO currently serving prestigious organizations like Berkshire Healthcare Systems. We are very excited to partner with Yankee Alliance."

08:37 EST Tilray announces portfolio expansion with Good Supply's launch of pre-rolls - Tilray Brands announced further portfolio expansion of their Canadian cannabis brand Good Supply, with the launch of their latest innovation of 'MONSTERS' infused pre-rolls. The Good Supply MONSTERS pre-rolls are made from a combination of two of our most potent signature strains frankensteined into a jaw-dropping pre-roll, coming in at a whopping 2.38g and 42.0% THC. Being the first of its kind, "MONSTERS" have been officially trademarked, differentiating its offerings from other infused pre-rolls products in the Canadian market.

08:33 EST Vir Biotechnology announces final draft guidance on sotrovimab from U.K.'s NICE - Biotechnology announced that the UK's National Institute for Health and Care Excellence, NICE, provided positive final draft guidance recommending the use of sotrovimab, an investigational SARS-CoV-2 neutralizing monoclonal antibody, in adults who do not need supplemental oxygen for COVID-19 and who have an increased risk for progression to severe COVID-19 where nirmatrelvir/ritonavir is contraindicated or unsuitable. "We welcome the final draft guidance from NICE which we believe is particularly meaningful as the organization's recommendations are informed by independent committees that aim to provide guidance to healthcare professionals on the best care options available to benefit their patients," said George Scangos, Ph.D., Chief Executive Officer of Vir. "With this recommendation, sotrovimab continues to be an important option for appropriate patients around the world and we remain committed to working with our partner GSK to ensure patients in need have access to it." This final draft guidance provides recommendations to the UK's National Health Service on the future routine commissioning of therapeutics for people with COVID-19 while COVID-19 is an endemic disease. NICE expects to publish its final recommendations on medicines to treat COVID-19 in March 2023.

08:31 EST Alarum to investigate potential illegal short selling - Alarum Technologies announced that it believes that its American Depository Shares have been a victim of trading abuses, which may be artificially depressing the Company's share price. Therefore, the Company's Board of Directors has approved the allocation of resources in order to evaluate all options to address this issue and prepare a concrete action plan. Shachar Daniel, Chief Executive Officer of Alarum said, "We feel we owe it to the company and to our shareholders to investigate this issue and establish appropriate action to make sure there is greater integrity in the capital markets. We have seen several companies commenting on this problem, and we would welcome the opportunity to collaborate with other companies that have been affected by these actions. We believe that our shares should be free from manipulation in order to accurately and fairly respond to the Company's true and actual performance and we are committed to protecting the interests of our shareholders and ensuring that the value of their investment is not artificially depressed." Mr. Daniel concluded.

08:27 EST Base Carbon completes project milestones ahead of schedule - Base Carbon provides an operational update regarding its initial projects. Highlights: Vietnam project partner SIPCO has completed the full distribution of project devices, an aggregate of 1.214 million fuel efficient cookstoves and water purifiers, four months ahead of the initial schedule and on budget. First issuance of carbon credits generated from the Vietnam project expected mid-2023. Citigroup is contracted to purchase initial 7.4 million carbon credits generated from the Vietnam project. Rwanda project partner DelAgua has completed the full distribution of 250,000 cookstoves, on schedule and on budget. Base Carbon and Danish Red Cross engage key project consultant to provide mapping and scoping services for Philippines blue carbon project. Base Carbon is pleased with the progress of both our Vietnam and Rwanda projects as we anticipate transitioning from a development stage to a revenue-generating company in 2023. Having now completed the distribution of cookstoves and water purifiers in Vietnam, the final stage of development involves initial project monitoring and reporting by an independent validation and verification body and the subsequent verification of the associated report by Verra, the project registry. In Rwanda, the project documentation has been submitted to Verra and the project is pending registration. The Company anticipates initial verification and issuance of carbon credits in mid-2023 for both the Vietnam and Rwanda projects. "Achieving full distribution of the Devices for our two initial carbon projects is foundational for our company. The Vietnam and Rwanda projects are expected to generate highly attractive capital returns for our shareholders as well as durable, additional, co-benefits for the environment and local communities. As our Company transitions to a revenue generating business, we look forward to continued capital deployments within voluntary carbon projects as we diversify our business and future revenue streams," stated CEO Michael Costa.

08:23 EST Voltus, Resideo, Google Nest, ecobee expand residential thermostat program - Voltus, together with Resideo Technologies (REZI), ecobee, and Google Nest (GOOG, GOOGL) announced the expansion of their residential smart thermostat demand response program offering to 1.2 million Ameren Illinois customers in more than 1,200 communities in the Midcontinent Independent System Operator territory.

08:21 EST Global Crossing Airlines announces IOSA certification - Global Crossing Airlines Group announced the completion of the International Air Transport Association International Operational Safety Audit and has been added to the IOSA Registry. The IATA Operational Safety Audit program is an internationally recognized and accepted evaluation system designed to assess the operational management and control systems of an airline. The certification is valid for two years, when it must be renewed.

08:19 EST SciSparc, Clearmind reveal three combinations of psychedelic-based compounds - SciSparc (SPRC) announced that as part of its ongoing collaboration with Clearmind Medicine Inc. (CMND), Clearmind has filed three provisional patent applications with the United States Patent and Trademark Office, for unique combinations of future psychedelic-based compounds.The patent applications refer to novel proprietary combinations of 3,4 Methylenedioxymethamphetamine, Ibogaine and Ketamine each with SciSparc's Palmitoylethanolamide, the active ingredient of its proprietary CannAmide. Overall, as part of this collaboration, six other patent applications have been filed by Clearmind with the USPTO for various combinations, three of them for the combination of SciSparc's PEA with Clearmind's MEAI compound for the treatment of alcohol use disorder, treatment of cocaine addiction and treatment of obesity and its related metabolic disorders, and recently for novel proprietary combinations of lysergic acid diethylamide, psilocybin, and N,N-dimethyltryptamine and SciSparc's PEA, the active ingredient of its proprietary CannAmide. As part of the collaboration agreement, any assets generated from the collaboration will belong to both companies.

08:18 EST Transcode Therapeutics signs non-binding LOI, JDA with BRAIN Biotech - TransCode Therapeutics announced the signing of a non-binding letter of intent, LOI, and a joint research and development agreement, JDA, with BRAIN Biotech AG. The objective of the JDA is to co-develop a platform technology that combines a Class 2 CRISPR nuclease, the cell-killing G-dase E, developed by BRAIN Biotech's Akribion Genomics unit with TransCode's TTX nucleic acid delivery platform for the treatment of cancer. "This partnership with BRAIN Biotech represents a significant milestone for TransCode because it further expands our broad pipeline to include cancer therapeutic candidates that rely not only on RNA interference, antisense technology, immune stimulation through pattern recognition receptors, or mRNA delivery, but also on CRISPR-derived genomic targeting. The partnership has the potential to enable a functionally unique tool to fight cancer because unlike our other therapeutic candidates, it does not rely on inhibition or enrichment of cancer-relevant genetic targets but, instead, is designed to specifically kill a cell with a critical pathway dysfunction," commented Michael Dudley, Co-founder, President and CEO of TransCode. Dudley added, "The timing of this partnership is ideal, given that we are in the process of initiating a first-in-human clinical trial aimed at demonstrating TTX's capability of targeting clinical metastases."

08:16 EST Aqua Metals recovers high-purity lithium hydroxide via Li AquaRefining - Aqua Metals announced the recovery of high-purity lithium hydroxide from lithium-ion battery black mass at the company's Li AquaRefining recycling facility located at the Tahoe-Reno Industrial Center. The production and availability of the first recycled lithium hydroxide at scale will help close the supply chain loop for critical battery metals in America, paving the way for a more sustainable, efficient battery manufacturing industry. The immediate recovery of lithium hydroxide also improves the economics of recycling advanced battery chemistries like lithium iron phosphate, where lithium makes up most of the valuable material, unlike current nickel and cobalt-based batteries.

08:14 EST SmileDirectClub adds sensitivity-free whitening kits to portfolio - SmileDirectClub announced the addition of a new Sensitivity-Free Whitening Kit to its innovative suite of premium, affordable oral care products. SmileDirectClub's new whitening innovation offers a powerful yet gentle solution that brightens teeth in 10 minutes a day. The Sensitivity-Free Whitening Kit features a new, ultra-gentle whitening formula that, when paired with the patented 20-LED wireless accelerator light, whitens teeth up to seven shades in just one week with low to no sensitivity. "As we continue our growth as a leader in the oral care category, we are pleased to bring new products to the market that answer our customers' needs," said John Sheldon, Chief Marketing Officer at SmileDirectClub. "With the launch of the Sensitivity-Free Whitening Kit, we are offering our Wireless LED Whitening Light, which utilizes advanced technology, along with a unique, ultra-gentle formula that offers customers with tooth sensitivity the benefit of whitening with comfort and ease."

08:12 EST SelectQuote appoints Ryan Clement as CFO - SelectQuote announced that the board of directors appointed Ryan Clement, SVP of financial planning and analysis, to serve as the company's CFO. Clement was named interim CFO in May 2022. Prior to joining SelectQuote in January as the SVP of financial planning and analysis, Clement served as the CFO of Sifted, a SaaS-based software technology company.

08:12 EST Kratos Defense releases OpenEdge products - Kratos Defense & Security Solutions released the first of its new OpenEdge products,an open standards-based and software-enabled satellite terminals. The company said, "Part of Kratos' OpenSpace Platform, OpenEdge is the first generally available family of satellite network edge devices employing a modern, software-defined approach for a range of communications, observation, sensing and TT&C uses. OpenEdge is the next step in Kratos' ongoing effort to support the mainstreaming of satellite services by enabling satellite ground systems to operate seamlessly with today's wireless and terrestrial networks. Until OpenEdge, satellite terminals- the devices that end users employ at the far edge of a satellite ground network to transmit and receive data- have been purpose-built hardware devices that seriously restrict functionality and flexibility at the network's edge. OpenEdge disrupts these limitations by: employing virtualized software modems that can run on general purpose, off-the-shelf compute, and adding far more power and versatility by enabling additional apps to run at the network's edge, fully orchestrated across service delivery."

08:10 EST Clearmind files patent applications for combos of psychedelic-based compounds - Clearmind Medicine (CMND) announced that it has filed three provisional patent applications with the United States Patent and Trademark Office, for unique combinations of future psychedelic-based compounds, as part of its ongoing collaboration with pharmaceutical company SciSparc (SPRC). The patent applications refer to novel proprietary combinations of 3,4-Methylenedioxymethamphetamine, Ibogaine, and Ketamine, each with Palmitoylethanolamide, the active ingredient of SciSparc's proprietary CannAmide. The applications reflect Clearmind's strategy of strengthening its IP portfolio to broaden the therapeutic psychedelic toolbox for patients with mental health disorders that require transformative medicines, and developing treatments that offer synergy, efficacy and safety while reducing cost. Clearmind has a broad IP footprint in the psychedelic space, with 29 patents in 13 patent families, of which 9 have been granted in major jurisdictions like the US, Europe, China, and India. Overall, as part of this collaboration, six other patent applications have been filed by Clearmind with the USPTO for various combinations, three of them for the combination of SciSparc's PEA with Clearmind's MEAI compound for the treatment of alcohol use disorder, treatment of cocaine addiction and treatment of obesity and its related metabolic disorders, and recently for novel proprietary combinations of lysergic acid diethylamide, psilocybin, and N,N-dimethyltryptamine and SciSparc's PEA, the active ingredient of its proprietary CannAmide.

08:10 EST Lineage Cell Therapeutics enters license agreement with Eterna Therapeutics - Lineage Cell Therapeutics announced that it has entered into an exclusive option and license agreement with Eterna Therapeutics for the development of novel beta 2 microglobulin, or B2M,-deficient induced pluripotent stem cell, or iPSC, lines, which Lineage will evaluate for development into differentiated cell transplant therapies. The new cell lines to be developed by Eterna will support the potential creation of additional product candidates at Lineage, specifically for the treatment of certain central nervous system, or CNS, disorders and other neurology indications. Eterna is the exclusive licensee of the key intellectual property underlying this collaboration from its discovery partner Factor Bioscience. Under the agreement, Eterna plans to conduct certain gene-editing activities and provide materials to Lineage for evaluation. The agreement provides Lineage an option to obtain an exclusive license to utilize and sublicense the novel gene-edited cell lines for preclinical, clinical, and commercial purposes in the field of CNS diseases. A feature of the starting cell line is the targeted deletion of the B2M gene, which is designed to reduce the immunogenicity of product candidates derived from the lines by inhibiting rejection by CD8+ T cells. Lineage expects this attribute will expand the edited cell lines' overall utility, including for non-immune privileged or non-human leukocyte antigen matched indications. Additional planned gene edits may further differentiate the cell line from others currently in use by competitors. Financial terms were not disclosed.

08:08 EST Amazon, NCSOFT in publishing pact for Throne and Liberty in the West and Japan - Amazon Games and NCSOFT announced an agreement to bring massively multiplayer online role-playing game THRONE AND LIBERTY to North America, South America, Europe, and Japan. Amazon Games will publish the highly anticipated title for PC, PlayStation 5, and Xbox Series X S, with support for cross-platform play... "NCSOFT has created some of the most popular and longest-running online games in the world, so it's no surprise that THRONE AND LIBERTY is among today's most anticipated MMOs," said Christoph Hartmann, VP, Amazon Games. "Publishing games that live and grow over time remains a critical piece of our strategy, and delivering games of the highest quality from the world's most talented developers is one of the cornerstones of our business. The last year has taught us a great deal about publishing and managing a successful live-service game on a global scale, and we're ready to bring THRONE AND LIBERTY players an incredible experience at launch."

08:07 EST Collegium Pharmaceutical publishes inaugural ESG report - Collegium Pharmaceutical announced the release of its inaugural Environmental, Social and Governance report. The report reflects the Company's long-standing commitment to operating with integrity, accountability and responsibility in all facets of its business while improving the health and well-being of the communities it serves. "Collegium is dedicated to serving as a responsible corporate citizen and holding ourselves accountable to the highest ethical standards as we advance our mission, support our communities and create shareholder value," said Joe Ciaffoni, CEO. "We are proud to issue our first ESG report as we anticipate a banner 2023 in which we accelerate our growth and deepen our collective impact."

08:07 EST GreenPower Motor EVs eligible for commercial clean vehicle credit under IRA - GreenPower Motor Company announced the company is now a qualified manufacturer for the commercial clean vehicle credit under the Inflation Reduction Act. GreenPower's all-electric commercial vehicle models weighing greater than 14,000 pounds GVWR are eligible for up to $40,000 in tax credits. Tax credits for vehicles weighing less than 14,000 pounds GVWR are available for up to $7,500.

08:06 EST Cue Biopharma enters collaboration, option agreement with Ono Pharmaceutical - Cue Biopharma (CUE) announced a collaboration and option agreement with Ono Pharmaceutical (OPHYL), for CUE-401, a bispecific protein designed to induce and expand regulatory T cells for the treatment of autoimmune and inflammatory diseases. The strategic collaboration with Ono is an important advancement in Cue Biopharma's corporate development plan to seek third party support to further develop its CUE-400 series and provides dedicated resources and capabilities to help advance CUE-401 toward the clinic. Under the terms of the agreement, Ono will pay Cue Biopharma an upfront payment and fully fund all research activities related to CUE-401 through a specified option period. During this option period Cue Biopharma will be responsible for the research and development of CUE-401. Upon Ono's exercise of its option to license CUE-401, Cue Biopharma will receive an option exercise payment and be eligible for development and commercial milestone payments up to an aggregate of approximately $220M, as well as tiered royalties on sales. Upon any such exercise, Ono will receive worldwide rights to develop and commercialize CUE-401, with Cue Biopharma retaining a 50% co-development and co-commercialization right in the United States. "This strategic collaboration with Ono Pharmaceutical, a leading Japanese pharmaceutical company with a track record of scientific innovation, is a significant accomplishment for Cue Biopharma, as it allows us to further develop this promising biologic through the support of a strategic partner," stated Daniel Passeri, chief executive officer of Cue Biopharma. "Through this important partnership we have secured resources and capabilities necessary to help advance CUE-401 towards the clinic, while preserving potential value to our shareholders through a 50:50 collaboration right for the U.S. market."

08:05 EST Wingstop sees about 240 global net new units in 2023 - Company expects the following for 2023, which is a 52-week fiscal year: Approximately 240 global net new units; SG&A of between $82.0 - $84.0 million; Stock-based compensation expense of between $11.5 - $12.5 million; and Depreciation and amortization of between $14.0 - $15.0 million.

08:04 EST Wingstop backs 3-5 year outlook of mid-single digit domestic SSS growth

08:01 EST Innoviz Technologies and General Laser announce collaboration - Innoviz Technologies and General Laser, a leading European provider of products and services in the fields of lasers, robotics, special machinery and more, announced their collaboration to drive sales for Innoviz's LiDAR solutions in the European market. This is Innoviz's first distribution agreement in Europe. General Laser will utilize its network of over 70 resellers and direct relationships with customers across Europe to accelerate the adoption of Innoviz's LiDAR solutions in General Laser's service territory across Europe. General Laser will help expand Innoviz's sales efforts into various industrial market segments, including construction, agriculture, mobile robotics, drones, surveillance and more, driving near-term revenues.

07:57 EST Intel provides update on effort to optimize cost structure - The company said, "In addition to its prudent capital allocation, Intel continues to take decisive actions to advance its strategy, optimize its cost structure and provide transparency to its stakeholders. These actions include: Delivering $3 billion in cost savings in 2023, on the path to $8 billion to $10 billion in annualized savings by the end of 2025. This includes the difficult steps previously taken to reduce headcount and the company's ongoing efforts to reduce other operating expenses. The company is also temporarily reducing compensation and rewards programs for employees and executives, and the board has decided to temporarily reduce its compensation as well. This is in addition to the exit of seven non-core businesses since early 2021, as the company continues to sharpen its focus and drive a best-in-class operating structure. Operating net CapEx intensity in the low 30% range in 2023 as the company prioritizes investment in strategic capital and adjusts the timing of capacity expansion in response to near-term changes in demand. Establishing an internal foundry model that will help Intel unleash the structural advantages of IDM 2.0 with a competitive cost structure and optimized operating model while providing further transparency into its strategic progress and performance against industry benchmarks. Advancing its Smart Capital strategy, which allows Intel to access new pools of capital that provide additional financial flexibility to invest for the long term while executing its transformation. This includes the innovative Semiconductor Co-Investment Program (SCIP), for which Intel intends to announce a second partner later this year."

07:53 EST Troika Media appoints Jefferies to optimize capital structure - Troika Media Group (TRKA) announces the engagement of Jefferies (JEF), a leading global, full-service investment banking firm to optimize TMG's existing capital structure and to explore strategic alternatives. TMG is a professional services company that architects and builds enterprise value in consumer brands to generate scalable performance driven revenue growth. The Company delivers three solutions pillars: TMG CREATES brands and experiences and CONNECTS consumers through emerging technology products and ecosystems to deliver PERFORMANCE based measurable business outcomes. Jefferies will lead the Company's efforts to optimize the Company's balance sheet and address its legacy capital structure, including its senior secured debt and to explore strategic alternatives. Willkie Farr & Gallagher is the Company's legal counsel.

07:51 EST Intel reduces quarterly dividend to 12.5c per share - Intel announced that its board of directors has reset its dividend policy, reducing the quarterly dividend to 12.5c per share on the company's common stock. The dividend will be payable on June 1 to stockholders of record on May 7. The company said, "The decision to decrease the quarterly dividend reflects the board's deliberate approach to capital allocation and is designed to best position the company to create long-term value. The improved financial flexibility will support the critical investments needed to execute Intel's transformation during this period of macroeconomic uncertainty. Since first initiated in 1992, Intel's dividend has delivered more than $80 billion in cash returns to the company's stockholders, and the board is committed to maintaining a competitive dividend."

07:46 EST Jeffs' Brands enters non-binding LOI for SuperBuzz collaboration - Jeffs' Brands has entered into a non-binding letter of Intent in order to establish a collaboration with SuperBuzz. Pursuant to the LOI, subject to the entry into one or more definitive agreements by the parties, Jeffs' Brands and SuperBuzz will collaborate on a joint project to create a software for Amazon's advertisement platform, based on AI technologies, including ChatGPT designed specifically for Jeffs' Brands' stores and brands, as well as opening a new line of service for marketing campaigns. Jeffs' Brands will allow SuperBuzz access to its Amazon platforms and brands, while SuperBuzz will provide Jeffs' Brands with a limited license to use its AI technologies. The collaboration is expected to yield improved targeting, maximize campaigns, and increase exposure and sales. Also pursuant to the LOI and subject to entry into a definitive agreement, Jeffs' Brands will have the option to invest up to $2M in SuperBuzz, at its sole discretion, for a period of 90 days following the execution of a definitive agreements.

07:45 EST Installed Building Products announces new $200M stock repurchase program - During the twelve months ended December 31 , IBP repurchased over 1.5M shares or approximately 5% of its common stock at a total cost of $137.6M, including commissions. At December 31 , the Company had $162 M of availability remaining under its stock repurchase program. Additionally, our board of directors authorized a new stock repurchase program that allows for the repurchase of up to $200M of our outstanding common stock. The new program replaces the previous program and is in effect through March 1, 2024.

07:44 EST Skeena Resources announces drilling results from Eskay Creek Project - Skeena Resources announced drilling results from the 2022 regional and near mine exploration and delineation campaigns at the Eskay Creek gold-silver Project in the Golden Triangle of British Columbia. This release completes the reporting for remaining drill holes from the 2022 program. Analytical results and reference images are detailed in this release as well as on the Company's website. 2022 Near Mine Exploration Drilling Highlights: 18.18 g/t Au, 130.2 g/t Ag over 9.26 m - 21A West Zone; 14.90 g/t Au, 2.5 g/t Ag over 5.70 m - 21A West Zone; 0.95 g/t Au, 1,003.3 g/t Ag over 6.42 m - 23 Zone; 1.11 g/t Au, 19.7 g/t Ag over 26.10 m - 23 Zone; 4.96 g/t Au, 14.6 g/t Ag over 25.98 m - 21E Zone; 3.39 g/t Au, 34.4 g/t Ag over 23.77 m - 21E Zone; 2.78 g/t Au, 59.0 g/t Ag over 20.49 m - 21E Zone.

07:41 EST ARway wins pilot contract with South American car rental company - ARway has won a pilot contract with the largest car rental network in South America, with over 452 locations. The AR navigation will initially be for travellers renting cars in branches located in airports and off airport locations. The Airport navigation is set to officially launch in Q2 2023, and once launched travellers from all over the world will be able to experience the convenience and ease of ARway navigation. ARway charges $600-$10,000 depending on the size of the pilot. After the pilot is completed the company charges $30,000/ annum plus .01/ sq ft. This contract initially has ARway launching at a single international airport, allowing travellers to easily find their way around the airport, saving them time and effort as they navigate to the rental car branch. This program includes AR wayfinding from baggage pickup to the transport depot, which includes car rentals, bus stops, Uber, etc. The partnership is for a single project at the branch in an airport in Sao Paulo. With the success of this project, a system-wide expansion to over 450 locations is planned.

07:39 EST Ebix signs debt extension amendment with existing lenders - Ebix announced that it has signed an amendment to its existing credit agreement, extending the maturity date to May 23, 2023. Amendment No. 13 provides for, among other things, an extension of the maturity date for both the revolving line of credit and the term loan, each as existing under the Credit Agreement. It was conditioned, among other things, upon the Company making a $5,000,000 prepayment of the Revolver and paying a customary consent fee.Amendment No. 13 modifies certain repayment provisions in the Credit Agreement to provide that each repayment of the Revolver shall be accompanied by a corresponding reduction of the aggregate revolving commitments, with amounts repaid on the Revolver not being available to be reborrowed and the Company shall be required to make an amortization payment on the Term Loan in an amount of $5,000,000 for the fiscal quarter ending March 31, 2023. Amendment No. 13 will result in an approximately 1.00% per annum interest rate increase for the interest period beginning February 21, 2023 compared to the interest period ended immediately prior thereto.

07:38 EST KemPharm announces corporate name change to Zevra Therapeutics - KemPharm announced that it changed its name to Zevra Therapeutics. This name change reflects the Company's intensified focus and dedication to developing transformational, patient-focused therapies for rare diseases with limited or no treatment options. In conjunction with the name change, the Company will begin trading under the new ticker symbol "ZVRA" on The Nasdaq Global Market on or about March 1, 2023. In May 2022, Zevra, then KemPharm, acquired arimoclomol, an orally-delivered, first-in-class investigational product candidate for the treatment of Niemann-Pick type C disease, from Orphazyme A/S as part of the Company's long-term vision to evolve into a commercially-driven rare disease therapeutics company. Through the acquisition, Zevra welcomed key new team members with years of valuable rare disease therapeutic research and development experience, maintained the ongoing early access programs and relationships with treatment centers in the U.S. and Europe, and continues to build upon longstanding partnerships within the NPC patient community. NPC, a rare disease with no currently approved treatments in the U.S., primarily affects children and is often fatal, causing progressive loss of brain, nerve, liver, spleen, bone marrow, and lung functions. The U.S. Food and Drug Administration has granted arimoclomol orphan drug designation, Fast Track designation, and rare pediatric disease designation for treating NPC. In addition to arimoclomol, Zevra is advancing KP1077, a product candidate based on Zevra's prodrug of d-methylphenidate, serdexmethylphenidate, which is currently being evaluated in a Phase 2 trial for the treatment of idiopathic hypersomnia, a rare sleep disorder. Pending the results from that trial, the Company plans to conduct a pivotal phase 3 study in IH, with the potential to study an expanded indication in narcolepsy. Zevra looks ahead to key milestones in 2023, including the resubmission of arimoclomol New Drug Application to the FDA as early as Q3 2023, an interim and final data readout for KP1077 in IH, and the potential achievement of certain commercial sales milestones for our partnered asset, AZSTARYS Along with the new name, the Company has a new logo and website.

07:36 EST AnPac Bio announces results from multi-cancer test follow-up study - AnPac Bio-Medical Science announced up-dated positive results from its first major multi-year and multi-cancer test follow-up study. To date, the study has enrolled over 18,000 individuals from a general population of 230,000 persons located in China. The test subjects were tested using AnPac Bio's Cancer Differentiation Analysis, or CDA, method. We believe that the study is one of the largest multi-year and multi-cancer follow-up studies in the world. The multi-year study fully validated that CDA method is a multi-cancer detection method which is capable of detecting multiple cancer types with statistical significance. We believe that the CDA method may become a cost effective, multi-cancer screening method.

07:35 EST BioSig Technologies regains compliance with all Nasdaq listing standards - BioSig Technologies announced that it has received written notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market notifying the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq because the bid price of the Company's common stock closed at or above $1.00 per share for a period of 10 consecutive business days, from February 6, 2023 to February 17, 2023. In addition, on February 21, 2023, the Company received a second written notice from Nasdaq notifying the Company that compliance with Nasdaq Listing Rule 5550(b) was regained by meeting an alternative compliance standard related to the market value of listed securities because the Company's MVLS had been $35 million or greater for a period of 11 consecutive business days, from January 31, 2023 to February 17, 2023. Per the notices, Nasdaq considers both matters closed.

07:32 EST Phio Pharmaceuticals names Robert Bitterman as CEO, effective Feb. 20 - Phio Pharmaceuticals announced that Robert Bitterman has been appointed by the Board of Directors to serve as the company's President and CEO, effective as of February 20. Bitterman has served as Interim CEO since September 2022. Bitterman will continue to serve as Chair of the Board, and as the company's principal executive officer and principal financial officer.

07:28 EST Allied Properties Real Estate renews normal course issuer bid - Allied Properties Real Estate Investment Trust announced that it has received approval from the Toronto Stock Exchange for a normal course issuer bid which will enable it to purchase up to 12,582,628 of its 127,955,983 issued and outstanding units as at February 10, 2023, representing approximately 10% of its public float of 125,826,281 Units as at that date. Allied intends to commence the NCIB on February 24, 2023. The NCIB will expire on February 23, 2024 or such earlier date as Allied completes its purchases pursuant to the NCIB. All purchases under the NCIB will be made on the open market through the facilities of the TSX or alternate trading systems in Canada at market prices prevailing at the time of purchase. In accordance with TSX rules, any daily repurchases will be limited to a maximum of 91,008 Units, representing 25% of the average daily trading volume of the Units on the TSX for the six months ended January 31, 2023. Any Units that are repurchased will either be cancelled or delivered to participants under Allied's restricted unit plan or to employees pursuant to Allied's employee programs. Under its normal course issuer bid that commenced on February 24, 2022, Allied sought and received approval from the TSX to purchase up to 12,602,594 Units and repurchased 76,697 Units at a weighted average price of $30.39 per Unit. Such purchases were effected through the facilities of the TSX. The primary purpose of the NCIB is to purchase Units to fulfil Allied's commitments to employees under its restricted unit plan and other employee programs. Allied may also purchase Units for cancellation from time to time, depending on the market price of the Units and other factors.

07:24 EST StateHouse enters cultivation partnership with Refined Genetics - StateHouse Holdings has entered into cultivation partnership with Refined Genetics. Through its strategic investments in plant genomics, breeding technologies, and commercial propagation, Refined Genetics is able to develop and deliver superior cultivars for the future of the cannabis industry. The purpose-driven, community-oriented company separates itself from other nurseries by unifying legacy cannabis operators and emerging businesses. The process of enriching and controlling flower quality through effective and efficient methods will begin at Refined Genetics' nursery in California. StateHouse and Refined Genetics will conduct quarterly performance trials before selecting promising, new genetics to participate in the Company's Genetics Trialing program. The innovative program will ramp stock of these genetics alongside a commercial-scale flower crop. Once harvested, greenhouse crop performance and finished flower will be evaluated by StateHouse's sales and marketing teams. StateHouse will then select and self-propagate the highest-performing genetics while honoring a royalty on every plant harvested.

07:23 EST Lizhi's social app TIYA launches 'TIYA Bot' powered by OpenAI's GPT-3 - LIZHI announced that its global social networking platform TIYA App has launched its "TIYA Bot" chatbot module powered by OpenAI's GPT-3 API. The TIYA Bot currently enables online Al dialogue and automated responses to users questions on the TIYA platform, and is available to a select group of users. The TIYA team will next be working on optimizing, training and fine-tuning the GPT-3 based model, including combining it with voice AI technologies such as Automatic Speech Recognition and Text-to-Speech to further enhance the TIYA Bot. Through incorporating social and interactive product features, the TIYA Bot aims to provide users an even richer and more diverse conversational experience.

07:21 EST Lifeist's Cannmart brand Roilty secures market share gains - Lifeist Wellness announced that CannMart's in-house brand, Roilty, has secured significant market share gains in Alberta, Ontario and the Prairies at one of Canada's largest cannabis retailers. The company said, "Roilty performance highlights across Canada: Ranked #1 overall concentrates brand across British Columbia, Alberta, Ontario, Saskatchewan and Manitoba; Ranked 3rd best selling live resin brand in Alberta, 9th in Ontario and 1st in Saskatchewan; Ranked 5th best selling shatter brand in Alberta, 7th in Ontario and 1st in Saskatchewan/ Notably, Roilty has become the most popular overall brand in concentrates in one of Canada's largest retailer networks, with 23% market share in the premium concentrates sub-category and 28% market share in the mid-range sub-category. Roilty live resin has three SKUs in Alberta, capturing 16% market share; and with only one live resin SKU in Ontario Roilty has 5% market share in the sub-category, and 30% in Saskatchewan with five SKUs. Roilty shatter products have 4% market share in Alberta and Ontario, most notably with only one SKU in Ontario, the Roilty Shatter Pack which launched in December 2022, and 50% market share with four SKUs in Saskatchewan."

07:19 EST View Smart Building Clouds certified as Accredited Data Provider by RESET - View announced View Smart Building Cloud has been certified as an Accredited Data Provider by RESET, recognizing the quality of data and integrations provided by View's platform that enable View's customers to achieve RESET air quality certifications. "Air and environmental quality data is critical to View's mission of improving the health and experience of building occupants. Our Smart Building Cloud platform enables us to achieve this mission," said Nitesh Trikha, Chief Product Officer of View. "The RESET accreditation further confirms the benefits of our platform and provides our customers with the assurance that their environmental monitoring is of the highest standards in the industry." RESET's Data Platform Accreditation means that View's systems can collect and organize data with the structure, resolution, and frequency required to meet the RESET Air Building Standards.

07:17 EST Poet Technologies, BFYY reach agreement on purchase of custom optical engines - POET Technologies announced an agreement with Beijing FeiYunYi Technologym, BFYY, to design optical engines for deployment in optical modules in the telecom market globally, beginning in China. The agreement, valued at up to $1M over a two-year period, includes NRE for POET and an initial purchase order for 10,000 units that will be used to sample customers. POET has agreed to design a single-chip optical engine solution, that incorporates complete transmit and receive functionalities for implementation in a 100G optical transceiver for BFYY's initial product offering. The unique single-chip solution, called "POET ONE", will offer significant performance advantages along with minimizing the transceiver design cycle time for BFYY. In addition to the cost benefits of POET's wafer-scale assembly, the single-chip solution will enable BFYY to cost effectively ramp to high-volume production. BFYY has forecasted optical engine purchases from SPX at over US$30 million over a three-year period.

07:14 EST Immunocore announces initial Phase 1 data for IMC-M113V - Immunocore has presented at the Conference on Retroviruses and Opportunistic Infection, CROI, the first safety and activity data with IMC-M113V, a bispecific soluble TCR therapy built on Immunocore's ImmTAX technology which is being developed for the treatment of people living with HIV. Initial Phase 1 trial data: In the single ascending dose part of the trial, three dose levels of IMC-M113V, given as a single IV infusion, were evaluated: a starting dose of 1.6 mcg, based on the minimum anticipated biological effect level (n=1), 5 mcg (n=1) and 15 mcg (n=10). All doses were well tolerated. There were no serious adverse events, significant changes in hematology or chemistry, nor cytokine release syndrome or neurotoxicity. Plasma viral load remained suppressed throughout dosing and follow-up. In addition, transient, dose-dependent increases in serum IL6 occurred 8-24 hours post-infusion. Five out of the ten participants who received the 15-mcg dose showed a greater than4-fold rise in IL6, which had been prespecified as indicative of pharmacodynamic activity based on prior experience from clinical trials with KIMMTRAK, the Company's first ImmTAX therapy now approved for the treatment of metastatic or unresectable uveal melanoma.

07:13 EST TPCO Holding, Gold Flora enter definitive business combination - TPCO Holding and Gold Flora announced that they have entered into a definitive business combination agreement to combine the companies in an all-stock merger. Under the terms of the Merger Agreement, The Parent Company shareholders will own approximately 49%, and Gold Flora holders will own approximately 51%, of the outstanding common equity of the combined company on a pro forma basis upon consummation of the Business Combination. Under the terms of the Merger Agreement, holders of TPCO Shares will receive one share of common stock in the capital of New Parent for each TPCO Share held pursuant to the Merger Agreement and holders of Gold Flora Units will receive 1.5233 New Parent Shares for each Gold Flora Unit held pursuant to the Merger Agreement, resulting in the issuance of an aggregate of approximately 312,138,271 New Parent Shares. The Business Combination values Gold Flora at $1.50 per Gold Flora Unit and The Parent Company at $0.9847 per TPCO Share. Following completion of the Business Combination, current holders of TPCO Shares will hold approximately 49% of New Parent and current holders of Gold Flora Units will hold approximately 51% of New Parent. In connection with the Business Combination, The Parent Company has agreed to make available to Gold Flora a line of credit of up to $5,000,000, which shall bear interest at a rate of 10% per annum, and shall be secured by certain assets of Gold Flora. The outstanding balance of the line of credit will become due and payable if the Merger Agreement is terminated, subject to certain conditions. It is anticipated that the line of credit shall be forgiven following completion of the Business Combination. The New Parent will operate as Gold Flora Corporation and is anticipated to remain a reporting issuer in Canada on the Neo Exchange and on the OTC Markets Group Inc, subject to receipt of all applicable stock exchange approvals. The Business Combination is expected to close before the end of the third quarter of 2023, following the satisfaction or waiver of closing conditions including, among others, approval by two-thirds of the votes cast by the shareholders of The Parent Company at the Meeting, the approval of the Supreme Court of British Columbia, and the approval of the NEO Exchange.

07:12 EST Charles River receives U.S. Department of Justice subpoena for NHP supply chain - The company received a subpoena from the U.S. Department of Justice relating to an investigation into the Cambodian non-human primate, or NHP, supply chain. The company has been informed that this investigation relates specifically to several shipments of NHPs received by Charles River from its Cambodian supplier. Charles River intends to fully cooperate with the U.S. government as part of their investigation. Due to ongoing investigations and the heightened focus on the Cambodian NHP supply chain in recent months, Charles River has voluntarily suspended NHP shipments from Cambodia at this time.

07:11 EST Aurora Cannabis and MedReleaf Australia to launch CraftPlant brand - Aurora Cannabis and MedReleaf Australia announced the launch of CraftPlant, a new medical cannabis brand for patients in the Australian market. The CraftPlant brand includes three new products available for doctors to prescribe - Greendae, Navana and HiVolt. All three are developed from ultra-premium cultivars and are THC-dominant with high percentages of terpenes. The cultivars were developed by Occo, Aurora's leading science and genetics business. The new range is produced under strict EU-GMP certified conditions and will be available in 10g containers. Aurora currently holds a 10% ownership stake in MedReleaf Australia, a fully licensed, private company. Together, they provide Australian patients with several Aurora-branded products, including dried flower, oils and soft gels.

07:06 EST Berry Corporation board increases share repurchase authorization to $200M - Beginning with first quarter 2023 results, in accordance with the updated shareholder return model, Berry plans to allocate Adjusted Free Cash Flow as follows: 80% primarily to share repurchases and debt repurchases, and 20% to variable dividends. Adjusted Free Cash Flow does not represent the total increase or decrease in our cash balance, and it should not be inferred that the entire amount of Adjusted Free Cash Flow is available for variable dividends, debt or share repurchases or other discretionary expenditures, since we have other non-discretionary expenditures that are not deducted from this measure and would be paid out of the 80% bucket, as necessary. The Board also increased the authorization for share repurchases to $200 million. The Board had previously authorized $75 million of debt repurchases all of which remains available.

07:05 EST Berry Corporation intends to double quarterly fixed dividend to 12c per share - In February 2023, the Company's Board of Directors declared dividends totaling $0.50 per share on the Company's outstanding common stock, comprising a fixed dividend of $0.06 per share and a variable dividend of $0.44 per share, based on fourth quarter 2022 Adjusted Free Cash Flow in accordance with the Company's shareholder return model. Both dividends are payable on March 23, 2023 to shareholders of record at the close of business on March 15, 2023. Cash dividends attributable to 2022 totaled $1.78 per share. Going forward, subject to declaration by the Board, the Company intends to double the fixed dividend to $0.12 per share quarterly or $0.48 per share annually; variable dividends will be paid in accordance with its shareholder return model.

07:01 EST NRx Pharmaceuticals issued patent by USPTO - NRx Pharmaceuticals announced that the U.S. Patent and Trademark Office, or USPTO, has issued U.S. Patent No. 11,576,911. This patent, issued to Glytech is exclusively licensed to NeuroRx, a wholly owned subsidiary of NRx, under the terms of a license agreement with Glytech through which NeuroRx has the sole rights to this and other patents, both U.S. and international. The licensed patents cover certain pharmaceutical formulations and their uses in treating a variety of neuropsychiatric conditions, including bipolar depression, major depressive disorder, PTSD, and suicidality. In particular, the claims of the new patent cover methods for treating a patient suffering from depression, including bipolar depression or major depression, with or without suicidality by administering to the patient an effective amount of the Company's lead product candidate, NRX-101. Should this drug candidate be approved by the FDA, this newly issued patent is expected to be listable in the FDA's "Orange Book" for NRX-101, which is currently undergoing clinical trials in the U.S. The 'patent represents the U.S. version of a third patent family owned by or exclusively licensed to NeuroRx that covers the NRX-101 formulation or its methods of use in treating depressive disorders, and such patent coverage is expected to remain in force through at least July 2033 prior to any patent term extensions available under federal law. Previously issued patents cover the NRX-101 composition of matter and methods for preventing akathisia, a common side effect of SSRI antidepressants.

06:53 EST Gildan Activewear sees FY23 EPS in line with FY22 - The company said, "A year ago, we provided an overview of Gildan's Sustainable Growth strategy focused on capacity driven growth, innovation and ESG. Our strong results are a testament to the progress we have made on this strategy. Specifically, with our FY22 revenue base of $3.240B, adjusted operating income of $639M and adjusted operating margin of 19.7% coming in at the higher end of our annual target range of 18% to 20%, our business model is positioning us well to deliver on our long-term profitability and return targets. Our leadership in pricing, product availability and sustainability, combined with our increased manufacturing flexibility is enabling us to grow our market share in key product categories. Further, we are well positioned to continue benefiting from favourable industry trends that are playing out such as the casualization of apparel, the interest for private label products, the impact of the creator economy and ongoing developments in digital printing, as well as the appeal of nearshoring and sustainable practices, all of which are creating long-term growth opportunities for Gildan given our competitive advantages. Notwithstanding these strong fundamentals, in the first part of 2023 we expect continued headwinds tied to the demand environment and to strong comparative periods, particularly as we cycle post pandemic inventory replenishment in the first quarter. We also expect increased margin pressure in early 2023 as we work through higher raw material and input costs currently in our inventories. However, as we move past the first quarter, we expect these headwinds to abate, enabling us to resume our growth trajectory and our path towards delivering on our performance targets. Accordingly, for 2023 we expect the following: Revenue growth for the full year to be in the low single digit range; Full year adjusted operating margin to fall within our 18% to 20% annual target range, despite expected margin pressure in the Q1 driving us 200 to 300 basis points below the low end of our target range; Capex to come in at the lower end of our previously stated 6% to 8% range; Strong free cash flow generation as significant investments in our inventories, which have put us in a strong position to service our customers, are now mostly behind us; Adjusted diluted EPS in line with 2022, which assumes the continuation of share repurchases aligned with our capital allocation targets of purchasing approximately 5% of the outstanding public float in 2023."

06:52 EST Nuvalent treatment of certain non-small cell lung cancer granted orphan status - Nuvalent's treatment of ROS1-positive, LTK-positive, ALK-positive, and NTRK fusion-positive non-small cell lung cancer was granted orphan status by the FDA, according to a post the agency's website. Reference Link

06:50 EST Pfizer's elranatamab receives FDA and EMA filing acceptance - Pfizer announced that the U.S. FDA has granted Priority Review for the company's Biologics License Application for elranatamab, an investigational B-cell maturation antigen CD3-targeted bispecific antibody, for the treatment of patients with relapsed or refractory multiple myeloma. Priority Review is intended to direct attention and resources from regulatory authorities toward drugs that, if approved, could offer significant improvements over existing options for serious conditions in order to make these drugs available to patients faster. The FDA's decision on the application is expected in 2023. The European Medicines Agency has also accepted elranatamab's marketing authorization application. The company is working closely with the EMA to facilitate their review and will provide updates on timing as appropriate.

06:47 EST AstraZeneca says Calquence tablet formulation approved in EU for CLL - AstraZeneca's tablet formulation of Calquence has been approved in the European Union for the treatment of adult patients with chronic lymphocytic leukaemia, or CLL, the company announced. The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use.

06:45 EST Teleflex announces key milestones in the release of two new catheters - Teleflex announced key milestones in the release of two new catheters: the U.S. FDA 510(k) clearance of the Triumph Catheter, and the first clinical use of GuideLiner Coast Catheter.

06:40 EST Evans Bancorp raises semi-annual cash dividend to 66c per share - The dividend is payable on April 4 to shareholders of record as of March 10.

06:37 EST Sage Therapeutics: EMA grants Orphan Drug Designation to SAGE-718 - Sage Therapeutics announced the European Medicines Agency granted Orphan Drug Designation to SAGE-718 for the treatment of Huntington's disease. SAGE-718 is in development as a potential oral therapy for cognitive disorders associated with NMDA receptor dysfunction. Multiple clinical studies are ongoing with SAGE-718 across several disease areas, including two placebo-controlled Phase 2 studies and a Phase 3 open-label safety study in the lead indication of HD-related cognitive impairment, and additionally Phase 2 placebo-controlled studies in mild cognitive impairment associated with Parkinson's disease and MCI and mild dementia due to Alzheimer's disease

06:26 EST Overstock.com falls 7% to $19.60 after Q4 results miss estimates

06:12 EST Sinovac Biotech extends expiration date of shareholder rights plan to Feb. 2024 - Sinovac Biotech announced that its board of directors has amended its shareholder rights plan. The amendment extends the expiration date of the plan from February 22, 2023 to February 22, 2024.

06:01 EST Lloyds Banking provides guidance for 2024 and 2026 - Based on the expected macroeconomic environment, the Group's strategy and investment and reflecting our growth potential, efficiency and the capabilities of our people, technology and data, the Group has enhanced its medium and longer-term guidance: Operating costs now expected to be c.GBP 9.2 billion in 2024, with a cost:income ratio of less than 50 per cent by 2026; Asset quality ratio now expected to be c.30 basis points in 2024; Return on tangible equity now expected to be c.13 per cent in 2024 and greater than 15 per cent by 2026; Additional revenues from strategic initiatives of c.GBP 0.7 billion by 2024 and c.GBP 1.5 billion by 2026; Risk-weighted assets to be between GBP 220 billion and GBP 225 billion at the end of 2024; Capital generation now expected to be c.175 basis points in 2024, increasing to greater than 200 basis points by 20266; The Group will maintain its progressive and sustainable ordinary dividend policy, whilst the Board expects to pay down to its target CET1 ratio by the end of 2024.

05:44 EST Nokia wins 10-year extension to 5G network deal with Antina - Nokia announced that it has won a ten-year extension to its existing nationwide 5G network deal with Antina, the joint venture formed by mobile network operators M1 and StarHub in Singapore, following a competitive tender process. The deal will see Nokia deploy a 5G Standalone network for both indoor and outdoor coverage as well as expand the existing network utilizing Antina's 3.5GHz spectrum holdings. The deal will improve the 5G connectivity experience for businesses and consumers underpinning Singapore's vibrant 5G ecosystem. Under the deal, Nokia will equip new buildings throughout the city-state with its AirScale indoor Radio, or ASiR, small cell solution for seamless indoor coverage. Nokia will also provide equipment from its latest energy-efficient AirScale portfolio including 5G base stations, massive MIMO adaptive antennas for urban and wide-area coverage as well as dual-band remote radio heads. Antina will utilize its spectrum in the 2.1 GHz and 3.5 GHz band which provides a good combination of capacity and coverage. All of these solutions will deliver an enhanced 5G user experience with high bandwidth, ultra-fast speeds, and low latency.

05:21 EST Stellantis announces EUR 1.5B share buyback - Stellantis board of directors approved a share buyback program of up to EUR 1.5B, to be executed on the market with the intent to cancel the common shares acquired through the share buyback program. The shares will be purchased over a period ending December 31 on NYSE / Euronext Milan / Euronext Paris. The opportunity to initiate the buyback program stems from the company's significant cash flow generation and strong balance sheet. These factors enable the company to ensure adequate liquidity to manage a wide variety of economic and market backdrops, while simultaneously facilitating attractive capital returns to shareholders.

05:13 EST iQIYI issues letter to investors regarding 2022 - The company said, "First, I would like to extend our sincerest gratitude for your trust and long-standing support. I am pleased to take this opportunity to share our business updates and some strategic considerations. 2022 was a challenging year for many, and also for us. Nevertheless, 2022 was a year of breakthroughs, a miraculous year for iQIYI, as we completed an iconic turnaround under extremely volatile market conditions. We made substantial breakthroughs in gaining market share, upgrading business operations and improving financial performance. Our long-term commitment to original content yielded exceptional results. iQIYI's brand perception was elevated, from "iQIYI can create blockbusters" to "iQIYI is a blockbuster powerhouse". Particularly in Q4'22, our market share, membership revenues, operating profits, operating cash flow and free cashflow all reached record highs. To be specific: We significantly improved our ability to produce and deliver high-quality original content of wide appeal to the public, enabling us to deliver a continuing stream of blockbusters. Take Q4'22 as an example: we launched 6 blockbuster dramas in a single quarter. The time spent by subscribers grew by over 40% year-over-year and by 30% quarter-over-quarter, which is unprecedented. In the meantime, we remained the dominant player in the content business and strengthened our leading position in the market. According to Enlightent, our market share in the exclusive drama category increased by 20 percentage points annually and 13 percentage points sequentially. Strong content drove strong revenue performance. In Q4'22, our core membership services business recorded its highest quarterly revenue, up 15% annually and 13% sequentially. In Q4'22, our average daily number of total subscribing members was 111.6 million, representing a sequential net addition of more than 10 million. The number of subscribing members as of the end of December 2022 was 119.7 million, representing a net addition of over 13 million compared with the end of September 2022. In the meantime, the advertising business continued to recover, with revenue increasing by 25% quarter-over-quarter. In terms of profitability, we had a record-setting quarter in Q4'22. Operating income reached a record high and operating margin expanded for a fifth consecutive quarter. The strong performance demonstrated the operating leverage embedded in our business model. We have successfully transformed into a cash-generating business. In Q4'22, we generated positive operating cash flow for three consecutive quarters... We are committed to providing users with the most appealing content, superior viewing experience and diverse benefits for subscribers. For example, we continued to improve our smart recommendation system to help users access their desired content as quickly and easily as possible. We provide industry-leading immersive content experience through interactive videos, which have been widely adopted in our drama and variety shows. Special APP modes were launched for teenagers, seniors and visually impaired users to meet their unique demands. We continued to expand our exclusive membership benefit package, including exclusive IP-based souvenirs, time-limited discount offers and exclusive fan events. In summary, we completed an iconic turnaround in 2022 and created a miraculous year for iQIYI. Looking ahead at 2023, our goal is to achieve "high-quality growth", focusing on growing both revenue and operating profit. In order to realize "high-quality growth", we will continue to emphasize investing in core businesses while cautiously evaluating new business opportunities. We will continue to invest in top class premium content, maintain a high-quality yet diversified content portfolio, and modestly increase marketing spend while ensuring desirable ROI. We also suggest that our investors to look beyond iQIYI's specific achievements, and re-assess the long-form video industry as a whole. While iQIYI continued to outperform in 2022, during the year ROI performance for the entire industry recovered quickly, driven by structural changes, especially a more concentrated supply of platform-originated content. This will lead to a healthier industry and every player in the industry will benefit from it. The future we have outlined will only come through sustained effort. We will stick to our commitments, and bring higher value to our users, business partners and our investors. We believe our best days are yet to come."

05:06 EST Scholastic announces strategic partnership with SoapBox Labs - Scholastic announced a multi-year, strategic partnership to voice enable its future reading products with SoapBox Labs' AI-based speech engine, built to accurately recognize children's voices and diagnose reading fluency and disfluencies, regardless of race, background, age or ethnicity. Ready4Reading, a new foundational skills curriculum, is Scholastic's first reading product to leverage SoapBox technology and will be available initially to U.S. schools and districts this summer. Ready4Reading is a supplemental print and digital K-3 phonics system that can be used in classrooms. Ready4Reading leverages a four-part instructional framework: Teach, Practice, Apply, Prove. The system features SoapBox's child-specific speech technology, offering kids opportunities to solidify learning through motivating, targeted practice and feedback, while providing teachers with the skills-level reporting they want to fine tune and differentiate lessons with ease.